

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center
 SEARCH REQUEST FORM

Requester's Full Name: Kahsay Habte Examiner #: 78271 Date: 10/25/05
 Art Unit: 1624 Phone Number: 2-0667 Serial Number: 10/763,742
 Location (Bldg/Room#): SC-15 (Mailbox #): SC-18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____


Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



$B = NR^1R^2, -CR^1R^2R^{10}, -C(=CR^2R^{10})R^1, -NHCRR^2R^{10} \dots$
 $-OCR^1R^2R^{10}, -SCR^1R^2R^{10}, CR^2R^{10}NHR^1, -CR^1R^{10}SR^1 \text{ or } -COR^2$

$R^3 = H, AK, -OAK, \text{ Halogen, alkyl-O-AK, Alkyl-OH}$
 or $S-AK$

→ Please see claim 9 for more information

STAFF USE ONLY		Type of Search	Vendors and cost where applicable	
Searcher: <u>Noble</u>		NA Sequence (#)	<input checked="" type="checkbox"/> STN	Dialog
Searcher Phone #:		AA Sequence (#)	<input type="checkbox"/> Questel/Orbit	Lexis/Nexis
Searcher Location:	<u>2</u>	Structure (#)	<input type="checkbox"/> Westlaw	WWW/Internet
Date Searcher Picked Up:		Bibliographic	<input type="checkbox"/> In-house sequence systems	
Date Completed: <u>10/25/05</u>	<u>10</u>	Litigation	<input type="checkbox"/> Commercial	<input type="checkbox"/> Oligomer
Searcher Prep & Review Time:		Fulltext	<input type="checkbox"/> Interference	<input type="checkbox"/> SPDI
Online Time:	<u>53</u>	Other	<input type="checkbox"/> Score/Length <input type="checkbox"/> Encode/Transl <input type="checkbox"/> Other (specify)	

=> d his

(FILE 'HOME' ENTERED AT 14:15:30 ON 25 OCT 2005)

FILE 'HCAPLUS' ENTERED AT 14:16:00 ON 25 OCT 2005

L1 1 (US2005009823 OR US6900217 OR US2002151713 OR US2001007867)/PN
 L2 11904 PFIZER/CS, PA
 E CHEN Y/AU
 L3 2387 E3,E26-28
 E CHEN YUH/AU
 E CHEN YUHPYNG/AU
 L4 63 E3-5

FILE 'REGISTRY' ENTERED AT 14:31:36 ON 25 OCT 2005

L5 STR
 L6 0 L5
 L7 STR L5
 L8 0 L7

FILE 'REGISTRY' ENTERED AT 14:41:58 ON 25 OCT 2005

FILE 'HCAPLUS' ENTERED AT 14:42:00 ON 25 OCT 2005
 L9 TRA L1 1- RN : 41 TERMS

FILE 'REGISTRY' ENTERED AT 14:42:00 ON 25 OCT 2005

L10 41 SEA L9
 L11 9 L10 AND N2C3-NCNC3/ES
 L12 STR L7
 L13 0 L12
 L14 STR L12
 L15 50 L14
 L16 STR L14
 L17 50 L16
 L18 2734 L16 FULL
 SAV TEM HAB742F0/A L18
 L19 STR L16
 L20 13 L19 SAM SUB=L18
 L21 304 L19 FULL SUB=L18
 SAV TEM HAB742S0/A L21

FILE 'HCAPLUS' ENTERED AT 15:44:09 ON 25 OCT 2005

L22 8 L21
 L23 2 L22 AND L1-4
 L24 6 L22 NOT L23

FILE 'HCAOLD' ENTERED AT 15:44:35 ON 25 OCT 2005

L25 0 L21

FILE 'USPATFULL, USPAT2' ENTERED AT 15:44:45 ON 25 OCT 2005

L26 6 L21
 E CHEN Y/AU
 L27 1 E13
 E CHEN YUHPYNG/AU
 L28 57 E3-5
 L29 4171 PFIZER/CS, PA
 L30 2 L26 AND L27-29
 L31 4 L26 NOT L30

=> b reg

FILE 'REGISTRY' ENTERED AT 15:46:58 ON 25 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2005 HIGHEST RN 865981-77-7
 DICTIONARY FILE UPDATES: 24 OCT 2005 HIGHEST RN 865981-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.






```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,      *
* effective March 20, 2005. A new display format, IDERL, is now        *
* available and contains the CA role and document type information.   *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta 121
 L16 STR



VAR G1=11/17/21/23/28/29/34

VAR G2=H/AK/X/36/39/41/43

VAR G3=46/47/O/S/CY

NODE ATTRIBUTES:

NSPEC IS RC AT 46

NSPEC IS RC AT 47

DEFAULT MLEVEL IS ATOM


DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 47

STEREO ATTRIBUTES: NONE

L18 2734 SEA FILE=REGISTRY SSS FUL L16
L19 STRAk—O—Ak
@36 37 38Ak—OH
@41 42S—Ak
@43 44



N 46



C @47

57
AkN—C—Ak
@51 52 5358
AkO—C—Ak
@54 55 5662
AkS—C—Ak
@59 60 61Ak—N—Ak
63 @64 65

Page 1-A

Cy—O—Ak
@68 69 70S—C
@71 72O—C
@73 74Ak—C—Ak
82 @83 84Ak—C=C—Ak
78 @79 80 81

Page 2-A

VAR G1=11/17/21/23/28/29/34

VAR G2=H/AK/X/36/39/41/43

VAR G3=47/47/51/54/59/49/64/68/71/73/76/79/83

VAR G4=N/O/S

NODE ATTRIBUTES:

NSPEC IS R AT 46

NSPEC IS R AT 47

NSPEC IS R AT 72

NSPEC IS R AT 74

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 84

STEREO ATTRIBUTES: NONE

L21 304 SEA FILE=REGISTRY SUB=L18 SSS FUL L19

100.0% PROCESSED 1973 ITERATIONS
 SEARCH TIME: 00.00.01

304 ANSWERS

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:47:04 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Oct 2005 VOL 143 ISS 18
 FILE LAST UPDATED: 24 Oct 2005 (20051024/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitstr l23 tot

```
L23 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:160837 HCAPLUS
DN 142:233372
ED Entered STN: 25 Feb 2005
TI Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal
IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-52
      ICS A61K031-454
INCL 514263220; 514263400; 514326000
CC 1-12 (Pharmacology)
      Section cross-reference(s): 4, 63
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005043327	A1	20050224	US 2004-870209	20040617
	WO 2005018645	A1	20050303	WO 2004-IB2596	20040809
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI US 2003-496803P P 20030821

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 2005043327	ICM	A61K031-52
	ICS	A61K031-454
	INCL	514263220; 514263400; 514326000
US 2005043327	NCL	514/263.220
	ECLA	A61K031/403+M; A61K031/4155+M; A61K031/4178+M; A61K031/454+M; A61K031/519+M; A61K031/52+M; A61K031/53+M; A61K031/5355+M; A61K045/06
WO 2005018645	ECLA	A61K031/403+M; A61K031/4155+M; A61K031/4178+M; A61K031/454+M; A61K031/519+M; A61K031/52+M; A61K031/53+M; A61K031/5355+M; A61K045/06

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

ST opioid CB1 antagonist combination addiction treatment; alc addiction treatment opioid CB1 antagonist combination; cocaine addiction treatment opioid CB1 antagonist combination; tobacco addiction treatment opioid CB1 antagonist combination

IT Behavior
(disorder, behavioral dependencies; opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT Behavior
(gambling; opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT Alcoholism
Combination chemotherapy
Drug delivery systems
Drug dependence
Drug withdrawal
Opioid antagonists
Prophylaxis
Tobacco smoke
(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT Behavior
(smoking; opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB1; opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT 50-36-2, Cocaine 64-17-5, Ethanol, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

IT	681178-21-2	681178-33-6	681178-46-1	681178-54-1	681178-94-9
	686344-19-4	686344-21-8	686344-22-9	686344-23-0	686344-24-1
	686344-25-2	686344-26-3	686344-27-4	686344-28-5	686344-29-6
	686344-30-9	686344-31-0	686344-33-2	686344-35-4	686344-36-5
	686344-37-6	686344-38-7	686344-39-8	686344-40-1	686344-41-2
	686344-42-3	686344-43-4	686344-44-5	686345-45-9	686347-23-9
	692257-76-4	709033-15-8	709033-17-0	709033-18-1	709033-19-2
	709033-20-5	709033-21-6	709033-22-7	709033-23-8	709033-25-0
	709033-27-2	709033-29-4	709033-30-7	709033-31-8	709033-32-9
	709033-33-0	709033-34-1	709033-35-2	709033-36-3	709033-37-4

709033-38-5	709033-39-6	709033-40-9	709033-41-0	709033-42-1
736993-28-5	736993-29-6	736993-30-9	736993-31-0	736993-50-3
736993-51-4	736993-52-5	736993-53-6	736993-54-7	736993-55-8
736993-56-9	736993-57-0	736993-58-1	736993-63-8	736993-64-9
736993-65-0	736993-66-1	736993-67-2	736993-68-3	736993-69-4
736993-70-7	736993-71-8	736993-76-3	736993-77-4	736993-82-1
736993-84-3	736993-86-5	736994-31-3	737827-71-3	737827-73-5
737827-74-6	737827-77-9	737827-81-5	737827-84-8	737828-12-5
737828-13-6	737828-23-8	737828-25-0	749207-87-2	
774240-03-8	774240-05-0	774240-35-6	774240-43-6	774240-48-1
774240-49-2	774241-06-4	774241-07-5	774241-45-1	774241-53-1
774241-58-6	774241-59-7	778582-19-7	778582-23-3	778582-27-7
778582-32-4	778582-34-6	778582-60-8	845621-26-3	845621-27-4
845621-28-5	845621-29-6	845621-30-9	845621-31-0	845621-32-1
845621-33-2	845621-34-3	845621-35-4	845621-36-5	845621-37-6
845621-38-7	845621-39-8	845621-40-1	845621-41-2	845670-44-2
845670-45-3	845670-46-4	845670-47-5	845670-48-6	845670-49-7
845670-50-0	845670-51-1	845670-52-2	845670-53-3	845670-54-4
845670-55-5	845670-56-6	845670-57-7	845670-58-8	845670-59-9
845670-60-2	845670-61-3			


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(opioid receptor antagonist-CB-1 receptor antagonist combination for
prevention and treatment of addiction)

IT 737828-12-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(opioid receptor antagonist-CB-1 receptor antagonist combination for
prevention and treatment of addiction)

RN 737828-12-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-methyl-
7-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



L23 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:654772 HCAPLUS
DN 141:190798
ED Entered STN: 13 Aug 2004
TI Preparation of pyrazolo[1,5-a]pyrimidine derivatives as cannabinoid
receptor ligands
IN Griffith, David A.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-541
ICS A61K031-5377; A61K031-519
INCL 514227800; 514234500; 514259300; 544060000; 544117000; 544280000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))


Section cross-reference(s) : 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157838	A1	20040812	US 2004-762959	20040121
	CA 2515596	AA	20040819	CA 2004-2515596	20040128
	WO 2004069838	A1	20040819	WO 2004-IB286	20040128
	W: AE, AG, AL, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-446450P	P	20030210		
	WO 2004-IB286	W	20040128		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 2004157838	ICM	A61K031-541
		ICS	A61K031-5377; A61K031-519
		INCL	514227800; 514234500; 514259300; 544060000; 544117000; 544280000
	US 2004157838	NCL	514/227.800
		ECLA	C07D487/04+239C+231C; C07D519/00+487/00+487/00
	WO 2004069838	ECLA	C07D487/04+239C+231C; C07D519/00+487/00+487/00
OS	MARPAT 141:190798		
GI			



AB Compds. of formula (I) [wherein R, R1 = each (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-4alkyl, halo-C1-4 alkyl, C1-4 alkoxy; R4 = Q, Q1, OR5 (where R5 taken together with R3 forms a 5- to 6-membered partially saturated heterocyclic ring optionally containing an addnl. oxygen, or a 5-membered heteroaryl, said heterocyclic ring and said heteroaryl being optionally substituted with one or more substituents); R4a = H, C1-3 alkyl; R4b, R4b', R4f, R4f' = H, cyano, HO, NH2, CONH2, C1-6 alkyl, C1-6 alkoxy, acyloxy, acyl, C1-3 alkoxycarbonyl, mono- or di(C1-4 alkyl)carbamoyl, mono- or di(C1-6 alkyl)amino, C3-6 cycloalkylamino, acylamino, aryl(C1-4 alkyl)amino, heteroaryl(C1-4 alkyl)amino, aryl, heteroaryl, each (un)substituted and partially or fully saturated 3-6 membered heterocycle or carbocyclic ring; or either R4b or R4b' taken together with R4e, R4e', R4f, or R4f' forms a bond, a methylene bridge, or an ethylene bridge; X, Z = a bond, (un)substituted CH2CH2; Y = O, S, CO, each]

(un)substituted CH₂CH₂ or NH] or pharmaceutically acceptable salt thereof, prodrugs of said compds. or said salts, or solvates or hydrates of said compds., said salts or said prodrugs are prepared. These compds. act as cannabinoid receptor ligands and are useful for treating disease, condition or disorder modulated by a cannabinoid receptor antagonist which is selected from the group consisting of weight loss, obesity, bulimia, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, alcoholism, tobacco abuse, dementia, seizure disorders, epilepsy, attention deficit disorder, Parkinson's disease, inflammation, gastrointestinal disorders, and type II diabetes. Thus, 1-[2-(2-chlorophenyl)-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide (90 mg, 0.17 mmol) was coupled with 4-chlorophenylboronic acid (41 mg, 0.26 mmol) in ethanol (2 mL), toluene (2 mL) and 2 M aqueous Na₂CO₃ (1 mL) in the presence of tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol) at 80° for 1 h to give 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide (62 mg, 72%).

ST pyrazolopyrimidine prepn cannabinoid receptor antagonist; wt loss obesity bulimia treatment pyrazolopyrimidine prepn; depression bipolar disorder treatment pyrazolopyrimidine prepn; psychoses schizophrenia treatment pyrazolopyrimidine prepn; behavioral addiction treatment pyrazolopyrimidine prepn; alcoholism tobacco abuse treatment pyrazolopyrimidine prepn; dementia seizure disorder treatment pyrazolopyrimidine prepn; epilepsy attention deficit disorder treatment pyrazolopyrimidine prepn; Parkinson disease treatment pyrazolopyrimidine prepn; inflammation gastrointestinal disorder treatment pyrazolopyrimidine prepn; type II diabetes treatment pyrazolopyrimidine prepn

IT Hormone receptors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MSH receptor analog, combination therapy; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Drugs of abuse
 (abuse of, tobacco abuse; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Nicotiana tabacum
 (abuse; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Mental disorder
 (attention deficit disorder; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Drug dependence
 (behavioral; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Mental disorder
 (bipolar disorder; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Ciliary neurotrophic factor
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Mental disorder
 (dementia; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Mental disorder
 (depression, atypical; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases

mediated by cannabinoid receptors)

IT Mental disorder
 (depression; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Body weight
 (loss; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Diabetes mellitus
 (non-insulin-dependent; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Alcoholism
 Anti-inflammatory agents
 Anticonvulsants
 Antidepressants
 Antidiabetic agents
 Antiobesity agents
 Antiparkinsonian agents
 Antipsychotics
 Bulimia
 Combination chemotherapy
 Digestive tract, disease
 Epilepsy
 Human
 Inflammation
 Obesity
 Parkinson's disease
 Schizophrenia
 Seizures
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Mental disorder
 (psychosis; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Behavior
 (suppression of reward-related behaviors; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Cannabinoid receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type CB1; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT Cannabinoid receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type CB2; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)


IT 53-43-0, Dehydroepiandrosterone 126339-09-1, Peptide YY3-36
 169494-85-3, Leptin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT 737827-67-7P, 3-(4-Chlorophenyl)-2-(2-chlorophenyl)-7-ethoxypyrazolo[1,5-a]pyrimidine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)

IT 1024-16-4P, 1-Benzyl-4-ethylaminopiperidine-4-carbonitrile 1027-91-4P,
 1-Benzyl-4-ethylaminopiperidine-4-carboxylic acid amide 84100-54-9P,
 4-Ethylaminopiperidine-4-carboxylic acid amide 96514-71-5P,
 3-(2-Chlorophenyl)-2-(4-chlorophenyl)-3-oxopropionitrile 126520-01-2P,
 [5-(2-Chlorophenyl)-1H-Pyrazol-3-yl]amine 138650-21-2P,
 1-Benzhydryl-3-benzylaminoazetidine-3-carbonitrile 333325-42-1P,
 2-(2-Chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-ol 686344-58-1P,
 1-Benzhydryl-3-benzylaminoazetidine-3-carboxylic acid amide
 686344-61-6P, 1-Benzhydryl-3-ethylaminoazetidine-3-carboxylic acid amide
 686344-69-4P, 1-Benzhydryl-3-methylaminoazetidine-3-carbonitrile
 686344-70-7P, 1-Benzhydryl-3-methylaminoazetidine-3-carboxylic acid amide
 686344-71-8P, 2-Benzhydryl-5-methyl-2,5,7-triazaspiro[3.4]oct-6-en-8-one
 686344-72-9P 686347-60-4P, 1-Benzhydryl-3-(benzylethylamino)azetidine-3-
 carboxylic acid amide 736994-07-3P 736994-10-8P 737827-52-0P,
 2-(2-Chlorophenyl)-7H-pyrazolo[1,5-a]pyrimidin-7-one 737827-53-1P,
 7-Chloro-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine 737827-54-2P,
 7-Chloro-2-(2-chlorophenyl)-3-iodopyrazolo[1,5-a]pyrimidine
 737827-55-3P, 3-Ethylaminopiperidine-3-carboxylic acid amide hydrochloride
 737827-56-4P, 7-Chloro-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-
 a]pyrimidine 737827-57-5P, 7-Chloro-2-(2-chlorophenyl)-3-ido-5-
 methylpyrazolo[1,5-a]pyrimidine 737827-58-6P, [5-(2-Chlorophenyl)-4-(4-
 chlorophenyl)-1H-pyrazol-3-yl]amine 737827-59-7P, 3-(4-Chlorophenyl)-2-
 (2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-ol 737827-60-0P,
 7-Chloro-3-(4-chlorophenyl)-2-(2-chlorophenyl)-6-methylpyrazolo[1,5-
 a]pyrimidine 737827-61-1P, 3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5-
 methylpyrazolo[1,5-a]pyrimidin-7-ol 737827-62-2P, 7-Chloro-3-(4-
 chlorophenyl)-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine
 737827-63-3P, 3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5,6-
 dimethylpyrazolo[1,5-a]pyrimidin-7-ol 737827-64-4P,
 7-Chloro-3-(4-chlorophenyl)-2-(2-chlorophenyl)-5,6-dimethylpyrazolo[1,5-
 a]pyrimidine 737827-65-5P, 2-(2-Chlorophenyl)-7-ethoxy-3-
 iodopyrazolo[1,5-a]pyrimidine 737827-66-6P, 3-(4-Chlorophenyl)-2-(2-
 chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ol 737827-68-8P,
 7-Chloro-3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine
 737827-69-9P, 6-Allyl-3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-
 a]pyrimidin-7-ol 737827-70-2P, 1-[2-(2-Chlorophenyl)-3-iodopyrazolo[1,5-
 a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide
 737827-75-7P, 1-[2-(2-Chlorophenyl)-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]-3-
 ethylaminoazetidine-3-carboxylic acid amide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of pyrazolo[1,5-a]pyrimidine derivs. as
 cannabinoid receptor ligands (antagonists) for treating diseases
 mediated by cannabinoid receptors)

IT 737827-71-3P, 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-
 a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide
 737827-72-4P, 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-
 a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide
 hydrochloride 737827-73-5P 737827-74-6P 737827-77-9P,
 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-
 ethylaminoazetidine-3-carboxylic acid amide 737827-78-0P 737827-79-1P,
 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-
 7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide 737827-81-5P,
 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5,6-dimethylpyrazolo[1,5-
 a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid Amide
 737827-82-6P, 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5,6-
 dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic
 acid amide hydrochloride 737827-83-7P 737827-84-8P 737827-85-9P
 737827-86-0P, 4-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5-
 methylpyrazolo[1,5-a]pyrimidin-7-yl]piperazine-1-carboxylic acid
 tert-butyl ester 737827-87-1P 737827-88-2P 737827-89-3P
 737827-90-6P 737827-91-7P 737827-92-8P 737827-93-9P 737827-94-0P
 737827-95-1P 737827-96-2P 737827-97-3P 737827-98-4P 737827-99-5P
 737828-00-1P 737828-01-2P 737828-02-3P 737828-03-4P,
 1-[4-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-
 a]pyrimidin-7-yl]piperazin-1-yl]ethanone 737828-04-5P 737828-05-6P

	737828-06-7P 737828-07-8P 737828-08-9P 737828-09-0P 737828-10-3P, 3-(4-Chlorophenyl)-2-(2-chlorophenyl)-7-isopropoxy-5-methylpyrazolo[1,5-a]pyrimidine 737828-11-4P, 7-(1-tert-Butylazetidin-3-yloxy)-3-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine 737828-12-5P 737828-13-6P 737828-14-7P 737828-15-8P, 3-(4-Chlorophenyl)-2-(2-chlorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyrimidine 737828-16-9P, 7-Allyloxy-3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine 737828-17-0P, 3,7-Bis(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine 737828-18-1P 737828-19-2P, 6-Bromo-5-butyl-3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-ethoxypyrazolo[1,5-a]pyrimidine 737828-20-5P, 5-Butyl-3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-ethoxypyrazolo[1,5-a]pyrimidine 737828-21-6P, 6-Bromo-3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-ethoxypyrazolo[1,5-a]pyrimidine 737828-22-7P 737828-23-8P, 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-methylaminoazetidine-3-carboxylic acid amide 737828-24-9P 737828-25-0P, 8-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)
IT	737827-80-4P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (reactant; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)
IT	67-63-0, Isopropanol, reactions 75-07-0, Acetaldehyde, reactions 75-36-5, Acetyl chloride 100-46-9, Benzylamine, reactions 107-18-6, Allyl alcohol, reactions 140-53-4, (4-Chlorophenyl)acetonitrile 141-97-9, Ethyl acetoacetate 557-66-4, Ethylamine hydrochloride 593-51-1, Methylamine hydrochloride 609-14-3, 2-Methyl-3-oxobutyric acid ethyl ester 1679-18-1, 4-Chlorophenylboronic acid 3612-20-2, N-Benzyl-4-piperidone 4637-24-5 6226-25-1, Trifluoromethanesulfonic acid 2,2,2-trifluoroethyl ester 7335-25-3, 2-Chlorobenzoic acid ethyl ester 7803-57-8, Hydrazine hydrate 13156-04-2, 1-tert-Butylazetidin-3-ol 40018-25-5, 2-Chlorobenzoylacetonitrile 40320-60-3, 1-Benzhydrylazetidin-3-one 57260-71-6 58986-28-0, Ethyl formylacetate sodium salt 75804-09-0, 3-Hydroxy-2-methylacrylic acid ethyl ester sodium salt 737827-76-8 RL: RCT (Reactant); RACT (Reactant or reagent) (reactant; preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)
IT	737828-11-4P, 7-(1-tert-Butylazetidin-3-yloxy)-3-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)
RN	737828-11-4 HCPLUS
CN	Pyrazolo[1,5-a]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[[1-(1,1-dimethylethyl)-3-azetidinyl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



=> d all hitstr 124 tot

L24 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:612294 HCAPLUS
 DN 143:133390
 ED Entered STN: 15 Jul 2005
 TI Preparation of pyrazolopyrimidines as CRF receptor antagonists
 IN Luo, Zhiyong; Slee, Deborah; Tellew, John Edward; Williams, John; Zhang, Xiaohu
 PA SB Pharma Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2

DT Patent
 LA English

IC ICM C07D487-04
 ICS A61K031-519

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063756	A1	20050714	WO 2004-IB4293	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-532044P P 20031222

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063756	ICM	C07D487-04
	ICS	A61K031-519

OS MARPAT 143:133390

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, NH2, (un)substituted alkyl, etc.; R2 = NR5R6 or OR7; R3 = H, alkyl or absent if double bond is present; Y = CO, =(CR4)-;

R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl; R5 = H, (un)substituted alkyl, heterocycle, etc.; R6 = (un)substituted alkyl, heterocyclealkyl, aryl, etc.; R7 = (un)substituted alkyl, arylalkyl, heteroarylalkyl, etc.) and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent substitution with isopropylamine. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

ST pyrazolopyrimidine prepn CRF receptor antagonist antidepressant antianxiety
 IT Mental disorder
 (depression; preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT Intestine, disease
 (irritable bowel syndrome; preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT Mental disorder
 (obsession-compulsion; preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT Antidepressants
 Human
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT Corticotropin releasing factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT Brain, disease
 (stroke; preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT 858520-93-1P 858521-24-1P 858523-08-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 IT 858520-82-8P 858520-83-9P 858520-84-0P
 858520-85-1P 858520-86-2P 858520-88-4P 858520-90-8P
 858520-91-9P 858520-92-0P 858520-95-3P 858520-97-5P
 858520-98-6P 858520-99-7P 858521-01-4P 858521-02-5P
 858521-03-6P 858521-04-7P 858521-05-8P 858521-06-9P
 858521-07-0P 858521-08-1P 858521-09-2P 858521-10-5P
 858521-11-6P 858521-12-7P 858521-13-8P 858521-14-9P
 858521-15-0P 858521-16-1P 858521-17-2P 858521-18-3P
 858521-19-4P 858521-20-7P 858521-21-8P 858521-22-9P
 858521-23-0P 858521-25-2P 858521-26-3P
 858521-27-4P 858521-28-5P 858521-29-6P 858521-30-9P
 858521-31-0P 858521-32-1P 858521-33-2P 858521-34-3P 858521-35-4P
 858521-36-5P 858521-37-6P 858521-38-7P 858521-39-8P
 858521-40-1P 858521-41-2P 858521-42-3P 858521-43-4P
 858521-44-5P 858521-45-6P 858521-46-7P 858521-47-8P
 858521-48-9P 858521-49-0P 858521-50-3P 858521-51-4P
 858521-52-5P 858521-53-6P 858521-54-7P 858521-55-8P
 858521-56-9P 858521-57-0P 858521-58-1P 858521-59-2P 858521-60-5P
 858521-61-6P 858521-62-7P 858521-63-8P 858521-64-9P 858521-65-0P
 858521-66-1P 858521-67-2P 858521-68-3P 858521-69-4P
 858521-70-7P 858521-71-8P 858521-72-9P 858521-73-0P
 858521-74-1P 858521-75-2P 858521-76-3P 858521-77-4P 858521-78-5P
 858521-79-6P 858521-80-9P 858521-81-0P 858521-82-1P 858521-83-2P
 858521-84-3P 858521-85-4P 858521-86-5P 858521-87-6P 858521-88-7P
 858521-89-8P 858521-90-1P 858521-91-2P 858521-92-3P 858521-93-4P
 858521-94-5P 858521-95-6P 858521-96-7P
 858521-97-8P 858521-98-9P 858521-99-0P
 858522-00-6P 858522-01-7P 858522-02-8P 858522-03-9P
 858522-04-0P 858522-05-1P 858522-06-2P
 858522-07-3P 858522-08-4P 858522-09-5P 858522-10-8P 858522-11-9P
 858522-12-0P 858522-13-1P 858522-14-2P 858522-15-3P

858522-17-5P 858522-18-6P 858522-19-7P 858522-20-0P 858522-21-1P
 858522-22-2P 858522-23-3P 858522-24-4P 858522-25-5P 858522-26-6P
 858522-27-7P 858522-28-8P 858522-29-9P 858522-30-2P 858522-32-4P
 858522-33-5P 858522-34-6P 858522-35-7P 858522-36-8P
 858522-37-9P 858522-38-0P 858522-39-1P
 858522-40-4P 858522-41-5P 858522-42-6P
 858522-43-7P 858522-44-8P 858522-45-9P
 858522-46-0P 858522-47-1P 858522-48-2P
 858522-49-3P 858522-50-6P 858522-51-7P
 858522-52-8P 858522-53-9P 858522-54-0P
 858522-55-1P 858522-56-2P 858522-57-3P
 858522-58-4P 858522-59-5P 858522-60-8P
 858522-61-9P 858522-62-0P 858522-63-1P
 858522-64-2P 858522-65-3P 858522-66-4P
 858522-67-5P 858522-68-6P 858522-69-7P
 858522-70-0P 858522-71-1P 858522-72-2P
 858522-73-3P 858522-74-4P 858522-75-5P
 858522-76-6P 858522-77-7P 858522-78-8P 858522-80-2P
 858522-82-4P 858522-83-5P 858522-84-6P
 858522-85-7P 858522-86-8P 858522-87-9P
 858522-88-0P 858522-89-1P 858522-90-4P
 858522-91-5P 858522-92-6P 858522-93-7P
 858522-95-9P 858522-96-0P 858522-97-1P
 858522-98-2P 858522-99-3P 858523-01-0P
 858523-02-1P 858523-03-2P 858523-04-3P
 858523-05-4P 858523-06-5P 858523-07-6P
 858523-09-8P 858523-11-2P 858523-12-3P 858523-14-5P
 858523-15-6P 858523-17-8P 858523-19-0P 858523-20-3P
 858523-21-4P 858523-22-5P 858523-23-6P 858523-24-7P 858523-25-8P
 858523-26-9P 858523-27-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 51-17-2, 1H-Benzimidazole 64-04-0, Benzeneethanamine 75-31-0,
 Isopropylamine, reactions 75-64-9, reactions 78-81-9 87-63-8,
 2-Chloro-6-methylaniline 89-93-0 96-20-8 97-13-2 100-46-9,
 Benzylamine, reactions 100-82-3 102-49-8 102-52-3, Malonaldehyde
 bis(dimethyl acetal) 103-55-9 104-86-9 104-89-2,
 5-Ethyl-2-methylpiperidine 105-04-4 109-05-7, 2-Methylpiperidine
 109-85-3, 2-Methoxyethylamine 109-89-7, Diethylamine, reactions
 109-97-7, Pyrrole 110-70-3, N,N'-Dimethylethylenediamine 110-73-6
 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions
 111-95-5 123-75-1, Pyrrolidine, reactions 123-83-1 138-39-6
 140-75-0 141-97-9, Ethyl acetoacetate 142-84-7, Dipropylamine
 271-63-6, 7-Azaindole 288-13-1, Pyrazole 288-32-4, Imidazole,
 reactions 288-36-8, 1,2,3-Triazole 288-42-6, Oxazole 288-88-0,
 1H-1,2,4-Triazole 459-46-1, 4-Fluorobenzyl bromide 460-32-2,
 3-Bromo-1,1,1-trifluoropropane 496-15-1 503-29-7, Azetidine
 504-03-0, 2,6-Dimethylpiperidine 608-31-1, 2,6-Dichloroaniline
 617-89-0, 2-Furanmethanamine 622-26-4, 4-Piperidineethanol 624-78-2
 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 635-46-1
 693-05-0 693-98-1 694-05-3 765-30-0, Cyclopropylamine 768-31-0,
 3-Trifluoromethylpiperidine 822-36-6 930-62-1 931-36-2 1072-62-4
 1193-12-0, 3,3-Dimethylpiperidine 1484-80-6, 2-Ethylpiperidine
 1484-84-0, 2-Piperidineethanol 1492-24-6, (S)-2-Aminobutyric acid
 1551-06-0, 2-Ethylpyrrole 1692-25-7, 3-Pyridylboronic acid 2032-33-9
 2199-43-1 2393-23-9 2516-34-9, Cyclobutanamine 2516-47-4,
 Cyclopropanemethanamine 2740-83-2 2969-81-5, Ethyl 4-bromobutyrate
 3238-60-6, 2-Propylpiperidine 3367-95-1 3731-51-9,
 2-Pyridinemethanamine 3731-52-0, 3-Pyridinemethanamine 3731-53-1,
 4-Pyridinemethanamine 4152-90-3 4393-16-2 4513-94-4,
 1H-Pyrrole-2-carbonitrile 4747-21-1 5071-96-5 5382-16-1,
 4-Hydroxypiperidine 5509-65-9, 2,6-Difluoroaniline 5856-62-2
 6165-68-0, 2-Thienylboronic acid 6165-69-1, 3-Thienylboronic acid
 6933-10-4, 4-Bromo-3-methylaniline 7554-65-6, 4-Methylpyrazole

13331-23-2, 2-Furanylboronic acid 14003-16-8 15862-72-3 19346-46-4,
 2-Fluoro-3-methyl-5-nitropyridine 20154-03-4, 3-Trifluoromethyl-1H-pyrazole 23056-33-9, 2-Chloro-4-methyl-5-nitropyridine 23356-96-9
 25016-17-5 26389-60-6 27492-84-8, Methyl 4-amino-2-methoxybenzoate
 27757-85-3, 2-Thiophenemethanamine 31230-17-8, 3-Amino-5-methylpyrazole
 31252-42-3, 4-Benzylpiperidine 31329-64-3 34322-82-2,
 (2-Methoxyethyl)ethylamine 36239-09-5, Ethyl malonyl chloride
 36764-94-0 36947-68-9 55552-70-0, Furan-3-boronic acid 55661-33-1,
 2-Thiazolemethanamine 57848-46-1 63126-47-6 63133-82-4 63448-63-5
 69807-81-4 70807-22-6, Cyanoacetone sodium salt 72235-53-1
 72235-56-4 82485-84-5 84025-81-0 93071-75-1 93919-56-3
 98198-48-2, 2-Amino-5-bromo-4-methylpyridine 104163-35-1 104678-13-9,
 2-(Methoxymethyl)piperidine 104678-18-4 116574-72-2,
 3-(Methoxymethyl)piperidine 130110-09-7 133200-67-6,
 2,5-Dihydroxytetrahydrofuran 135884-31-0 144851-61-6 154016-48-5
 158296-69-6 177842-14-7 188582-62-9, 4-Bromo-2-fluorobenzyl alcohol
 244022-71-7 249624-84-8 306934-85-0 306934-92-9 352018-93-0
 763120-58-7 847818-55-7 858523-63-4 858523-65-6 858523-67-8
 858523-69-0 858523-70-3 858523-71-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 1212-57-3P 27166-46-7P 43192-33-2P 56545-22-3P 112626-91-2P
 136549-13-8P 744209-96-9P 744210-03-5P 744210-14-8P 858523-28-1P
 858523-29-2P 858523-30-5P 858523-31-6P 858523-32-7P 858523-33-8P
 858523-34-9P 858523-35-0P 858523-36-1P 858523-37-2P 858523-38-3P
 858523-39-4P 858523-40-7P 858523-41-8P 858523-42-9P 858523-43-0P
 858523-44-1P 858523-45-2P 858523-46-3P 858523-47-4P 858523-48-5P
 858523-49-6P 858523-50-9P 858523-51-0P 858523-52-1P 858523-53-2P
 858523-54-3P 858523-56-5P 858523-58-7P 858523-60-1P 858523-61-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Chen, C; JOURNAL OF MEDICINAL CHEMISTRY 2004, V47(19), P4787 HCPLUS
- (2) He, L; US 6313124 B1 2001 HCPLUS
- (3) Janssen Pharmaceutica N V; WO 9729109 A 1997 HCPLUS
- (4) Merck & Co Inc; WO 9854093 A 1998 HCPLUS
- (5) Neurogen Corporation; WO 0123388 A 2001 HCPLUS
- (6) Pfizer Products Inc; EP 1097709 A 2001 HCPLUS
- (7) Taisho Pharmaceutical Co Ltd; WO 0202549 A 2002 HCPLUS

IT 858523-08-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RN 858523-08-7 HCPLUS

CN Butanoic acid, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 858520-82-8P 858520-84-0P 858520-85-1P
 858520-86-2P 858520-91-9P 858520-92-0P
 858521-02-5P 858521-04-7P 858521-11-6P
 858521-17-2P 858521-22-9P 858521-23-0P
 858521-25-2P 858521-26-3P 858521-27-4P
 858521-40-1P 858521-41-2P 858521-44-5P
 858521-48-9P 858521-54-7P 858521-55-8P
 858521-70-7P 858521-71-8P 858521-95-6P
 858521-96-7P 858521-97-8P 858521-98-9P
 858522-00-6P 858522-04-0P 858522-05-1P
 858522-06-2P 858522-14-2P 858522-15-3P
 858522-36-8P 858522-37-9P 858522-38-0P
 858522-39-1P 858522-40-4P 858522-41-5P
 858522-42-6P 858522-43-7P 858522-44-8P
 858522-45-9P 858522-46-0P 858522-47-1P
 858522-48-2P 858522-49-3P 858522-50-6P
 858522-51-7P 858522-52-8P 858522-53-9P
 858522-54-0P 858522-55-1P 858522-56-2P
 858522-57-3P 858522-58-4P 858522-59-5P
 858522-60-8P 858522-61-9P 858522-62-0P
 858522-63-1P 858522-64-2P 858522-65-3P
 858522-66-4P 858522-67-5P 858522-68-6P
 858522-69-7P 858522-71-1P 858522-72-2P
 858522-73-3P 858522-74-4P 858522-75-5P
 858522-76-6P 858522-80-2P 858522-82-4P
 858522-83-5P 858522-84-6P 858522-85-7P
 858522-86-8P 858522-87-9P 858522-88-0P
 858522-89-1P 858522-90-4P 858522-91-5P
 858522-92-6P 858522-93-7P 858522-95-9P
 858522-96-0P 858522-97-1P 858522-98-2P
 858522-99-3P 858523-01-0P 858523-02-1P
 858523-03-2P 858523-04-3P 858523-05-4P
 858523-06-5P 858523-07-6P 858523-11-2P
 858523-14-5P 858523-15-6P 858523-26-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 858520-82-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858520-84-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858520-85-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858520-86-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 858520-91-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,N,2,5-tetramethyl- (9CI) (CA INDEX NAME)




RN 858520-92-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-02-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,1-dimethylethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-04-7 HCAPLUS

CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]methylamino]- (9CI) (CA INDEX NAME)




RN 858521-11-6 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 858521-17-2 HCAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 858521-22-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 858521-23-0 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 858521-25-2 HCAPLUS
 CN 1,2-Ethanediamine, N- [3- [2-methoxy-4- (1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N- (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858521-26-3 HCAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N- [3- [2-methoxy-4- (1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-27-4 HCAPLUS
 CN 1,2-Ethanediamine, N,N,N'-triethyl-N' - [3- [2-methoxy-4- (1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 858521-40-1 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N',N'-trimethyl-1-phenyl- (9CI)
(CA INDEX NAME)




RN 858521-41-2 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N',N'-tris(1-methylethyl)- (9CI)
(CA INDEX NAME)




RN 858521-44-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(4-fluorophenyl)ethyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI)
(CA INDEX NAME)




RN 858521-48-9 HCPLUS

CN Ethanol, 2-[ethyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 858521-54-7 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 858521-55-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858521-70-7 HCPLUS

CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 858521-71-8 HCPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858521-95-6 HCPLUS


CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858521-96-7 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858521-97-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 858521-98-9 HCPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858522-00-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 858522-04-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-(1H-imidazol-1-yl)-2-methoxyphenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858522-05-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858522-06-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-

4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-14-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-15-3 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 858522-36-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-37-9 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-38-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 858522-39-1 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 858522-40-4 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858522-41-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-42-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-43-7 HCPLUS

CN Benzonitrile, 3-[(2-methoxyethyl)[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl- (9CI) (CA INDEX NAME)




RN 858522-44-8 HCPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858522-45-9 HCPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI)
(CA INDEX NAME)

RN 858522-46-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI)
(CA INDEX NAME)


RN 858522-47-1 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(2-methyl-4-thiazolyl)methyl]- (9CI)
(CA INDEX NAME)




RN 858522-48-2 HCAPLUS

CN Benzonitrile, 4-[(2-methoxyethyl)[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl- (9CI) (CA INDEX NAME)




RN 858522-49-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-50-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[3-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(9CI) (CA INDEX NAME)




RN 858522-51-7 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 858522-52-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858522-53-9 HCAPLUS

R: 035311-11-1
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)-(9CI) (CA INDEX NAME)




RN 858522-54-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(2-(trifluoromethoxy)phenyl)methyl]-(9CI) (CA INDEX NAME)




RN 858522-55-1 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(2-(difluoromethoxy)phenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-(9CI) (CA INDEX NAME)




RN 858522-56-2 HCPLUS

CN 1,2-Ethanediamine, N-[(4-fluorophenyl)methyl]-N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-57-3 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858522-58-4 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[(3-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858522-59-5 HCPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)




RN 858522-60-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-61-9 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-62-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 858522-63-1 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 858522-64-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-65-3 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 858522-66-4 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 858522-67-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 858522-68-6 HCPLUS

CN Propanenitrile, 3-[ethyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 858522-69-7 HCPLUS

CN Propanenitrile, 3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858522-71-1 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(1H-imidazol-1-yl)propyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-72-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 858522-73-3 HCPLUS

CN Propanenitrile, 3-[[2-(3,4-dimethoxyphenyl)ethyl][3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 858522-74-4 HCPLUS

CN Propanenitrile, 3-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(2-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858522-75-5 HCPLUS

CN Propanenitrile, 3-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 858522-76-6 HCPLUS

CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl][3-(4-morpholinyl)propyl]amino]-(9CI) (CA INDEX NAME)




RN 858522-80-2 HCPLUS

CN Butanoic acid, 4-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 858522-79-9

CMF C29 H30 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 858522-82-4 HCAPLUS

CN Butanoic acid, 4-[(3-[(2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 858522-81-3
CMF C31 H34 N6 O3

CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 858522-83-5 HCPLUS

CN Heptanoic acid, 7-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858522-84-6 HCPLUS

CN Octanoic acid, 8-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858522-85-7 HCPLUS

CN Pentanoic acid, 5-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858522-86-8 HCPLUS

CN Hexanoic acid, 6-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858522-87-9 HCAPLUS

CN Heptanoic acid, 7-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858522-88-0 HCAPLUS

CN Pentanoic acid, 5-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858522-89-1 HCAPLUS


CN Hexanoic acid, 6-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858522-90-4 HCAPLUS
 CN Octanoic acid, 8-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 858522-91-5 HCAPLUS
 CN β -Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 858522-92-6 HCAPLUS
 CN β -Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858522-93-7 HCAPLUS

CN Nonanoic acid, 9-[(3-[(2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2-phenylmethyl] (CA INDEX NAME)




RN 858522-95-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-2,5-dimethyl-3-[3-methyl-5-(1H-pyrazol-1-yl)-2-pyridinyl]-, mono(trifluoroacetate) (CA INDEX NAME)

CM 1

CRN 858522-94-8


CMF C21 H25 N7




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 858522-96-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-2,5-dimethyl-3-[3-methyl-5-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 858522-97-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1H-pyrazol-1-yl)-2-pyridinyl]-N-(phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 858522-98-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 858522-99-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-2,5-dimethyl-3-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 858523-01-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl-3-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-00-9


CMF C23 H28 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 858523-02-1 HCPLUS


CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858523-03-2 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-chloro-4-(1H-pyrazol-1-yl)phenyl]-N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858523-04-3 HCPLUS
 CN 1,2-Ethanediamine, N-[3-[2-chloro-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858523-06-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl-3-[4-methyl-6-(1H-pyrazol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 858523-07-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[4-methyl-6-(1H-pyrrol-1-yl)-3-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 858523-11-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-N-(2-methoxyethyl)-2,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-10-1


CMF C22 H25 F N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 858523-14-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-13-4


CMF C24 H27 F3 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 858523-15-6 HCPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-fluoropropyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858523-26-9 HCPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[7-[ethyl(2-methoxyethyl)amino]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-3-methoxyphenyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 6 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:612293 HCPLUS
 DN 143:133389
 ED Entered STN: 15 Jul 2005
 TI Preparation of pyrazolopyrimidines as CRF receptor antagonists
 IN Luo, Zhiyong; Sree, Deborah; Tellew, John Edward; Williams, John; Zhang, Xiahou
 PA SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D487-04
 ICS A61K031-495
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005063755	A1	20050714	WO 2004-IB4234	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-532031P P 20031222

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063755	ICM C07D487-04 ICS A61K031-495	

OS MARPAT 143:133389

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted alkyl, heteroaryl, etc.; R2 = (un)substituted alkyl, aryl, aryloxyalkyl, etc.; R3 = H, alkyl or absent if double bond is present; Y = CO, -(CR4)-; R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent Suzuki coupling with 2-methoxyphenylboronic acid. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

ST pyrazolopyrimidine prepn CRF receptor antagonist antidepressant antianxiety

IT Appetite
(anorexia nervosa; preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Mental disorder
(depression; preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Intestine, disease
(irritable bowel syndrome; preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Mental disorder
(obsession-compulsion; preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Antidepressants

Anxiety

Anxiolytics

Human
(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Corticotropin releasing factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT Brain, disease
(stroke; preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 859158-61-5P 859159-37-8P 859159-49-2P 859159-50-5P
859159-51-6P 859159-55-0P 859159-78-7P 859159-79-8P
859159-89-0P 859160-12-6P 859160-27-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 859158-53-5P 859158-54-6P 859158-55-7P
859158-56-8P 859158-57-9P 859158-58-0P
859158-59-1P 859158-60-4P 859158-62-6P
859158-63-7P 859158-64-8P 859158-65-9P
859158-66-0P 859158-67-1P 859158-68-2P
859158-69-3P 859158-70-6P 859158-71-7P
859158-72-8P 859158-73-9P 859158-74-0P
859158-75-1P 859158-76-2P 859158-77-3P
859158-79-5P 859158-81-9P 859158-82-0P
859158-83-1P 859158-84-2P 859158-85-3P
859158-86-4P 859158-88-6P 859158-90-0P
859158-91-1P 859158-92-2P 859158-94-4P
859158-96-6P 859158-97-7P 859158-98-8P
859158-99-9P 859159-00-5P 859159-01-6P
859159-02-7P 859159-03-8P 859159-04-9P
859159-05-0P 859159-06-1P 859159-07-2P
859159-08-3P 859159-09-4P 859159-10-7P
859159-11-8P 859159-12-9P 859159-13-0P
859159-14-1P 859159-15-2P 859159-16-3P
859159-17-4P 859159-18-5P 859159-19-6P
859159-20-9P 859159-21-0P 859159-22-1P
859159-23-2P 859159-24-3P 859159-25-4P
859159-26-5P 859159-27-6P 859159-28-7P 859159-29-8P
859159-30-1P 859159-31-2P 859159-32-3P

859159-33-4P 859159-34-5P 859159-35-6P 859159-36-7P
 859159-38-9P 859159-39-0P 859159-40-3P 859159-41-4P 859159-42-5P
 859159-43-6P 859159-44-7P 859159-45-8P 859159-46-9P 859159-47-0P
 859159-48-1P 859159-52-7P 859159-53-8P 859159-54-9P
 859159-56-1P 859159-57-2P 859159-58-3P 859159-59-4P
 859159-61-8P 859159-62-9P 859159-63-0P 859159-65-2P
 859159-66-3P 859159-67-4P 859159-68-5P
 859159-69-6P 859159-70-9P 859159-71-0P
 859159-72-1P 859159-73-2P 859159-74-3P
 859159-75-4P 859159-76-5P 859159-77-6P
 859159-80-1P 859159-82-3P 859159-85-6P
 859159-87-8P 859159-88-9P 859159-90-3P
 859159-91-4P 859159-92-5P 859159-93-6P
 859159-94-7P 859159-95-8P 859159-96-9P
 859159-97-0P 859159-98-1P 859159-99-2P
 859160-00-2P 859160-01-3P 859160-02-4P
 859160-03-5P 859160-05-7P 859160-06-8P 859160-07-9P
 859160-08-0P 859160-09-1P 859160-10-4P 859160-11-5P 859160-13-7P
 859160-14-8P 859160-15-9P 859160-16-0P 859160-17-1P 859160-18-2P
 859160-19-3P 859160-21-7P 859160-22-8P 859160-23-9P 859160-24-0P
 859160-25-1P 859160-26-2P 859160-29-5P 859160-30-8P
 859160-31-9P 859160-32-0P 859160-33-1P
 859160-34-2P 859160-35-3P 859160-36-4P
 859160-37-5P 859160-38-6P 859160-40-0P
 859160-41-1P 859160-42-2P 859160-69-3P
 859161-36-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 75-31-0, Isopropylamine, reactions 98-80-6 102-52-3, Malonaldehyde bis(dimethyl acetal) 106-48-9, 4-Chlorophenol 108-91-8, Cyclohexylamine, reactions 108-95-2, Phenol, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 141-97-9, Ethyl acetoacetate 151-18-8, 3-Aminopropionitrile 288-13-1, Pyrazole 348-60-7, 4-Chloro-3-fluorophenol 348-62-9, 4-Chloro-2-fluorophenol 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 402-45-9, 4-(Trifluoromethyl)phenol 503-29-7, Azetidine 615-79-2, Ethyl-2,4-dioxovalerate 616-47-7, 1-Methylimidazole 626-58-4, 4-Methylpiperidine 693-98-1, 2-Methylimidazole 694-05-3, 1,2,3,6-Tetrahydropyridine 767-00-0, 4-Cyanophenol 930-36-9, 1-Methylpyrazole 1003-03-8, Cyclopentylamine 1068-55-9, Iso-propylmagnesium chloride 1423-27-4 1692-15-5 1765-93-1 1993-03-9 2516-34-9, Cyclobutylamine 3197-42-0, (S)-2-Methylpiperidine 3430-17-9, 2-Bromo-3-methylpyridine 3900-89-8 4093-29-2 4363-35-3, 2-Phenylethenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0 6165-68-0 6165-69-1 6933-10-4, 4-Bromo-3-methylaniline 10365-98-7 13331-23-2 14047-29-1 16114-47-9 16419-60-6 19346-46-4, 2-Fluoro-3-methyl-5-nitropyridine 22237-13-4 23056-33-9, 2-Chloro-4-methyl-5-nitropyridine 23112-96-1 25487-66-5 27492-84-8, Methyl 4-amino-2-methoxybenzoate 31230-17-8, 3-Amino-5-methylpyrazole 33252-28-7, 2-Chloro-5-cyanopyridine 34420-17-2 38256-93-8, N-(2-Methoxyethyl)-N-methylamine 40138-16-7, 2-Formylphenylboronic acid 40972-86-9 55552-70-0 56039-93-1, 3-Butenylmagnesium chloride 56824-22-7, 2-(2-Chloroethyl)-1-methylpyrrolidine hydrochloride 58379-80-9, 1-Tosylethylisocyanide 62306-79-0 70799-12-1 70807-22-6, Cyanoacetone sodium salt 78495-63-3 89641-18-9 89694-48-4 90002-36-1 94839-07-3 98198-48-2, 2-Amino-5-bromo-4-methylpyridine 99768-12-4 99769-19-4 105869-40-7 109299-78-7 118062-05-8 121219-16-7 122775-35-3 123088-59-5 126747-14-6 127972-00-3 127972-02-5 133200-67-6 133472-27-2, 4-Fluorophenylzinc chloride 133730-34-4 135884-31-0, N-Boc-pyrrole-2-boronic acid 144025-03-6 149104-88-1 149104-90-5 149105-19-1 156545-07-2 162607-15-0 163105-89-3 166316-48-9 174669-73-9 175676-65-0 175883-60-0 177735-09-0 179113-90-7 179897-94-0 182163-96-8 190903-71-0

204841-19-0 221006-70-8 352303-67-4 355004-67-0 373384-18-0
 374538-03-1 380430-53-5, (2-Ethoxycarbonyl)phenylboronic acid
 405520-68-5 458532-97-3 756520-78-2 762287-57-0 762287-59-2
 763120-55-4 847818-55-7 850991-69-4 859160-65-9 859160-66-0
 859160-67-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

IT 15367-24-5P 27166-46-7P 112626-91-2P 136549-13-8P 744209-96-9P
 744210-03-5P 744210-14-8P 744210-26-2P 858523-28-1P 858523-29-2P
 858523-30-5P 858523-31-6P 858523-32-7P 858523-33-8P 858523-45-2P
 858523-46-3P 858523-48-5P 858523-49-6P 858523-50-9P 858523-53-2P
 858523-54-3P 859160-44-4P 859160-45-5P 859160-46-6P 859160-47-7P
 859160-48-8P 859160-50-2P 859160-51-3P 859160-52-4P
 859160-54-6P 859160-55-7P 859160-56-8P 859160-57-9P 859160-58-0P
 859160-59-1P 859160-60-4P 859160-61-5P 859160-62-6P
 859160-63-7P 859160-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Chen, C; WO 9729109 A 1997 HCPLUS

(2) He, L; US 6313124 B1 2001 HCPLUS

IT 859158-61-5P 859159-78-7P 859159-79-8P


859159-89-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 859158-61-5 HCPLUS

CN Benzoic acid, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-78-7 HCPLUS

CN Benzenemethanol, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-79-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(chloromethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859159-89-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



IT 859158-53-5P 859158-54-6P 859158-55-7P
 859158-56-8P 859158-57-9P 859158-58-0P
 859158-59-1P 859158-60-4P 859158-62-6P
 859158-63-7P 859158-64-8P 859158-65-9P
 859158-66-0P 859158-67-1P 859158-68-2P
 859158-69-3P 859158-70-6P 859158-71-7P
 859158-72-8P 859158-73-9P 859158-74-0P
 859158-75-1P 859158-76-2P 859158-77-3P
 859158-79-5P 859158-81-9P 859158-82-0P
 859158-83-1P 859158-84-2P 859158-85-3P
 859158-86-4P 859158-88-6P 859158-90-0P
 859158-91-1P 859158-92-2P 859158-94-4P
 859158-96-6P 859158-97-7P 859158-98-8P
 859158-99-9P 859159-00-5P 859159-01-6P
 859159-02-7P 859159-03-8P 859159-04-9P
 859159-05-0P 859159-06-1P 859159-07-2P
 859159-08-3P 859159-09-4P 859159-10-7P
 859159-11-8P 859159-12-9P 859159-13-0P
 859159-14-1P 859159-15-2P 859159-16-3P
 859159-17-4P 859159-18-5P 859159-19-6P
 859159-20-9P 859159-21-0P 859159-22-1P
 859159-23-2P 859159-24-3P 859159-25-4P
 859159-26-5P 859159-27-6P 859159-30-1P
 859159-31-2P 859159-32-3P 859159-35-6P
 859159-53-8P 859159-56-1P 859159-65-2P
 859159-66-3P 859159-67-4P 859159-68-5P
 859159-69-6P 859159-70-9P 859159-71-0P
 859159-72-1P 859159-73-2P 859159-74-3P
 859159-75-4P 859159-76-5P 859159-77-6P
 859159-80-1P 859159-82-3P 859159-85-6P
 859159-87-8P 859159-88-9P 859159-90-3P


859159-91-4P 859159-92-5P 859159-93-6P
 859159-94-7P 859159-95-8P 859159-96-9P
 859159-97-0P 859159-99-2P 859160-00-2P
 859160-01-3P 859160-02-4P 859160-03-5P
 859160-05-7P 859160-31-9P 859160-32-0P
 859160-33-1P 859160-34-2P 859160-35-3P
 859160-36-4P 859160-37-5P 859160-38-6P
 859160-40-0P 859160-42-2P 859160-69-3P
 859161-36-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 859158-53-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-54-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3,5-dimethyl-4-isoxazolyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-55-7 HCPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-6-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-56-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2,4-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859158-57-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(1,3-benzodioxol-5-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-58-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(4-fluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-59-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-60-4 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-62-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,4-dimethoxy-5-pyrimidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-63-7 HCPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-64-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(5-chloro-2-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-65-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 859158-66-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(3-fluoro-2-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-67-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-pyridinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859158-68-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 859158-69-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2,4-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-70-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 859158-71-7 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 859158-72-8 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,3-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-73-9 HCPLUS

CN Benzenesulfonamide, 3-methoxy-4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-74-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859158-75-1 HCPLUS


CN Benzaldehyde, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, oxime (9CI) (CA INDEX NAME)




RN 859158-76-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(4-methoxy-3-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859158-77-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-phenyl- (9CI) (CA INDEX NAME)




RN 859158-79-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(4-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-81-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,6-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-82-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 859158-83-1 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 859158-84-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2-furanyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859158-85-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(5-methyl-2-furanyl)- (9CI) (CA INDEX NAME)




RN 859158-86-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(3-furanyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-88-6 HCPLUS

CN Ethanone, 1-[4-[(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 859158-90-0 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-chlorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-91-1 HCPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-(2-methoxy-5-methylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-92-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(3,4-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859158-94-4 HCAPLUS
 CN Benzamide, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859158-96-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(5-fluoro-2-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-97-7 HCAPLUS

CN Ethanone, 1-[3- [3- [2-methoxy-4- (1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 859158-98-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3-chloro-4-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859158-99-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(4-chloro-2-methoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-00-5 HCPLUS

CN Methanesulfonamide, N-[2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 859159-01-6 HCPLUS

CN Benzoic acid, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 859159-02-7 HCPLUS

CN Benzoic acid, 3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 859159-03-8 HCAPLUS

CN Benzoic acid, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 859159-04-9 HCAPLUS

CN Benzamide, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-05-0 HCAPLUS


CN Benzoic acid, 3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-06-1 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 859159-07-2 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 859159-08-3 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(4-ethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-09-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(3-fluoro-4-pyridinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859159-10-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(5-methoxy-3-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-11-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859159-12-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(6-methoxy-3-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-13-0 HCAPLUS

CN Benzenepropanoic acid, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-14-1 HCAPLUS


CN Benzoic acid, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-15-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(3,5-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859159-16-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)




RN 859159-17-4 HCAPLUS
 CN Benzenemethanamine, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-18-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,3-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-19-6 HCAPLUS

CN Benzonitrile, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-20-9 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 859159-21-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2,6-dimethoxy-3-pyridinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-22-1 HCAPLUS
 CN Benzaldehyde, 4-methoxy-3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-23-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 859159-24-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-methyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 859159-25-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 859159-26-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 859159-27-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,2-difluoro-1,3-benzodioxol-5-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-30-1 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-31-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 859159-32-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859159-35-6 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 859159-53-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-methanol, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]- α , α ,2,5-tetramethyl- (9CI) (CA INDEX NAME)

RN 859159-56-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-methanol, α,α -diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-65-2 HCPLUS

CN Benzenemethanamine, N-cyclopentyl-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859159-64-1


CMF C₃₀ H₃₂ N₆ O



CM 2


CRN 76-05-1

CMF C₂ H F₃ O₂




RN 859159-66-3 HCPLUS

CN Benzenemethanamine, N-cyclohexyl-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-67-4 HCAPLUS

CN Benzenemethanamine, N-cyclobutyl-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl] - (9CI) (CA INDEX NAME)




RN 859159-68-5 HCAPLUS

CN Benzenemethanamine, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(1-methylethyl) - (9CI) (CA INDEX NAME)




RN 859159-69-6 HCAPLUS

CN Benzenemethanamine, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethyl - (9CI) (CA INDEX NAME)




RN 859159-70-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 859159-71-0 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 859159-72-1 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-[(2S)-2-methyl-1-piperidinylmethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859159-73-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(4-methyl-1-piperidinyl)methyl]phenyl- (9CI) (CA INDEX NAME)




RN 859159-74-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(4-thiomorpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 859159-75-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(1-azetidinylmethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-76-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-[(3,6-dihydro-1(2H)-pyridinyl)methyl]phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-77-6 HCPLUS

CN Benzenemethanamine, N-(2-methoxyethyl)-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 859159-80-1 HCPLUS

CN Benzeneacetonitrile, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859159-82-3 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-[2-(4-morpholinyl)ethyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859159-81-2


CMF C30 H32 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859159-85-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 859159-84-5


CMF C29 H27 N7 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 859159-87-8 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-[2-(4-thiomorpholinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859159-88-9 HCPLUS
 CN Benzeneethanamine, N-(2-methoxyethyl)-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 859159-90-3 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 859159-91-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859159-92-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(2-methoxy-3-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-93-6 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 859159-94-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(6-methoxy-2-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859159-95-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859159-96-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859159-97-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859159-99-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-7-(3-methoxy-2-pyridinyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859160-00-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 859160-01-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-methoxyphenyl)-2,5-dimethyl-3-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 859160-02-4 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-chloro-4-(1H-pyrazol-1-yl)phenyl]-7-(2-fluoro-3-methoxyphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 859160-03-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-methoxyphenyl)-2,5-dimethyl-3-[2-methyl-3-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 859160-05-7 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-methoxyphenyl)-2,5-dimethyl-3-[3-methyl-5-(1H-pyrazol-1-yl)-2-pyridinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 859160-04-6


CMF C24 H21 F N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 859160-31-9 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(methoxymethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859160-32-0 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[2-[(2-methoxyethoxy)methyl]phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859160-33-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(ethoxymethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859160-34-2 HCAPLUS

CN Morpholine, 4-[2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]benzoyl- (9CI) (CA INDEX NAME)




RN 859160-35-3 HCAPLUS

CN Benzamide, N-cyclopentyl-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859160-36-4 HCAPLUS

CN Benzamide, N-cyclobutyl-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859160-37-5 HCPLUS

CN Benzamide, N-(2-cyanoethyl)-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-(9CI) (CA INDEX NAME)




RN 859160-38-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(1-ethyl-1H-pyrrol-2-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 859160-40-0 HCPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 859160-42-2 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 859160-69-3 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2-fluoro-3-methoxyphenyl)-2,5-dimethyl-3-[4-methyl-6-(1H-pyrazol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 859161-36-7 HCPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(1-ethyl-1H-imidazol-5-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



IT 859160-48-8P 859160-50-2P 859160-59-1P
 859160-60-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 RN 859160-48-8 HCPLUS
 CN Benzaldehyde, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 859160-50-2 HCPLUS

CN Benzeneacetaldehyde, 2-[3-[(2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859160-49-9


CMF C26 H23 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 859160-59-1 HCPLUS

CN Benzoyl chloride, 2-[3-[(2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, (9CI) (CA INDEX NAME)



RN 859160-60-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



L24 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:71176 HCAPLUS
 DN 142:176857
 ED Entered STN: 27 Jan 2005
 TI Preparation of fused aryl and heteroaryl derivatives, in particular pyrazolo[3,4-d]pyrimidines, as modulators of G-coupled protein receptor and their use in the prophylaxis and treatment of metabolic disorders
 IN Jones, Robert M.; Semple, Graeme; Xiong, Yifeng; Shin, Young-Jun; Ren, Albert S.; Calderon, Imelda; Fioravanti, Beatriz; Choi, Jin Sun Karoline; Sage, Carlton R.
 PA Arena Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 320 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D487-04
 ICS C07D473-00; C07D498-04; C07D471-04; C07D215-22; A61K031-519; A61K031-52; A61K031-4375; A61K031-47; A61P003-00; A61P003-10
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007658	A2	20050127	WO 2004-US22417	20040713
	WO 2005007658	A3	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2005059650 PRAI US 2003-487443P US 2003-510644P	A1 P P	20050317 20030714 20031010	US 2004-890549	20040713
CLASS				
PATENT NO.		CLASS	PATENT FAMILY CLASSIFICATION CODES	
-----		-----	-----	
WO 2005007658	ICM	C07D487-04		
	ICS	C07D473-00; C07D498-04; C07D471-04; C07D215-22; A61K031-519; A61K031-52; A61K031-4375; A61K031-47; A61P003-00; A61P003-10		
WO 2005007658	ECLA	C07D215/22C; C07D471/04+221B+221B+2; C07D471/04+239B+221B; C07D473/00B2A; C07D487/04+239B+231B; C07D487/04+239C+231C; C07D487/04+249B+239B; C07D498/04+261B+239B		
	US 2005059650	NCL	514/210.210	
ECLA		C07D215/22C; C07D471/04+221B+221B+2; C07D471/04+239B+221B; C07D473/00B2A; C07D487/04+239B+231B; C07D487/04+239C+231C; C07D487/04+249B+239B; C07D498/04+261B+239B		

OS MARPAT 142:176857
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A, B = independently (un)substituted alkylene; D = O, S, SO, SO₂, etc.; E = N, C, CH and derivs.; K = (un)substituted cyclo/alkylene; Q = NH and derivs., O, S, SO, SO₂; T, M, J = independently N, CH and derivs.; U, W, Z = independently C, N; V = a bond, N, CH and derivs.; X, Y = independently O, S, N, CH and derivs., NH and derivs.; Ar₁ = (un)substituted hetero/aryl; their pharmaceutically acceptable salts, hydrates and solvates] were prepared as modulators, in particular agonists and inverse agonists of G-coupled protein receptor (RUP3), for treating diabetes, hyperglycemia and other metabolic disorders. Ten biol. examples are given. For example, II was prepared, in 5 steps, from 4-(methylsulfonyl)phenylhydrazine•HCl, ethoxymethylenemalononitrile and 4-chloro-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine. Selected I displayed EC₅₀ < 10 μM in a melanophore-based pigment dispersion assay. Selected RUP3 agonists I lowered blood glucose levels in rats in an oral glucose tolerance test. Thus, I are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

ST pyrazolopyrimidine prepn metab G coupled protein receptor inverse agonist; diabetes obesity G coupled protein receptor agonist pyrazolopyrimidine prepn; hyperglycemia antidiabetic hypertriglyceridemia hypercholesterolemia fused aryl heteroaryl prepn

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Metabolism, animal
(disorder, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dyslipidemia, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Lipids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hyperlipidemia, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Autoimmune disease
 (insulin-dependent diabetes mellitus, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Diabetes mellitus
 (insulin-dependent, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inverse agonists; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Disease, animal
 (metabolic syndrome X, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Diabetes mellitus
 (non-insulin-dependent, treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Anticholesteremic agents
 Antidiabetic agents
 Human
 Hypolipemic agents
 (preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT Hypercholesterolemia
 Hyperglycemia
 Hypertriglyceridemia
 (treatment; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 832714-06-4P, 4-[(1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester 832714-19-9P, 1-(4-Methylsulfonylphenyl)-4-[(piperidin-4-yl)oxy]-1H-pyrazolo[3,4-d]pyrimidine 832714-42-8P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[(piperidin-4-yl)oxy]-1H-pyrazolo[3,4-d]pyrimidine 832714-45-1P, 4-[(1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester 832714-89-3P 832715-06-7P 832715-08-9P, 4-[(1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl]piperidine-1-carboxylic acid tert-butyl ester 832715-45-4P, (5-Aminopyridin-2-yl)[4-[(1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy]piperidin-1-yl]methanone trifluoroacetate 832715-50-1P, 4-[(1-(4-Bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832715-72-7P, trans-[4-[(1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]cyclohexyl]carbamic acid tert-butyl ester 832716-02-6P 832716-69-5P, 4-(1-Benzylazetidin-3-yloxy)-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 832717-22-3P, 4-[[3-(4-Methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 352530-44-0P, 2-Fluoro-4-bromophenylzinc iodide 832714-09-7P,
 4-[[1-(4-Methylsulfonylphenyl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832714-13-3P,
 4-[[1-(4-Methylsulfonylphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832714-17-7P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isobutyl ester 832714-18-8P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832714-20-2P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-21-3P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid butyl ester 832714-23-5P,
 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl]piperidine-1-carboxylic acid cyclopropylmethyl ester
 832714-25-7P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl]piperidine-1-carboxylic acid cyclobutylmethyl ester
 832714-26-8P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl]piperidine-1-carboxylic acid
 2-cyclopropylethyl ester 832714-27-9P, (5-Bromofuran-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl]piperidin-1-yl]methanone 832714-28-0P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid pentyl ester 832714-29-1P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid 1-ethylpropyl ester 832714-30-4P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid 2-ethylbutyl ester 832714-31-5P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid cyclopentylmethyl ester 832714-32-6P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid 2,2-dimethylpropyl ester
 832714-33-7P, (5-Butylpyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-34-8P,
 (4-Difluoromethoxyphenyl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-36-0P,
 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832714-40-6P,
 2-[4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(4-trifluoromethoxyphenyl)ethanone
 832714-43-9P, 2-[4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(3-fluorophenyl)ethanone
 832714-44-0P, 2-[4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(pyridin-2-yl)ethanone
 832714-46-2P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832714-50-8P, (4-Ethylpyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-51-9P, (5-Bromopyridin-3-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-52-0P, (5-Ethylpyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-53-1P, (4-Ethoxyphenyl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-54-2P, (5-Butylpyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832714-55-3P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-isopropoxymethylpyridin-2-yl)methanone 832714-59-7P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-isopropoxypyridin-2-yl)methanone 832714-61-1P,

4- [{1- (2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-5'-isopropoxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
 832714-63-3P, 1- (2-Fluoro-4-methylsulfonylphenyl)-4- {[1- (4-trifluoromethoxyphenyl)piperidin-4-yl]oxy}-1H-pyrazolo[3,4-d]pyrimidine
 832714-64-4P, 1- (2-Fluoro-4-methylsulfonylphenyl)-4- {[1- (3-trifluoromethoxyphenyl)piperidin-4-yl]oxy}-1H-pyrazolo[3,4-d]pyrimidine
 832714-65-5P, 5'-Fluoro-4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
 832714-66-6P, 4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-5'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 832714-67-7P,
 4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 832714-68-8P,
 (5'-Fluoro-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl) [1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine
 832714-69-9P, (6-Chloropyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-70-2P,
 (5-Chloropyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-71-3P,
 [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy}piperidin-1-yl] (1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)methanone 832714-72-4P, (2-Chloropyridin-4-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-74-6P, (4-Hydroxy-3-methoxyphenyl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-75-7P, (4-Chloro-3-nitrophenyl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-76-8P, 1- [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]3-methylbutan-1-one
 832714-77-9P, [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl] [6-(pyrazol-1-yl)pyridin-3-yl]methanone
 832714-78-0P, (2-Hydroxypyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-79-1P,
 (5,6-Dichloropyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-80-4P,
 (5-Bromopyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-81-5P,
 5- {[4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy}piperidin-1-yl]carbonyl}nicotinic acid 832714-82-6P,
 (1H-Imidazol-4-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-83-7P,
 [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy}piperidin-1-yl] [6-(pyrrolidin-1-yl)pyridin-3-yl]methanone
 832714-84-8P, (6-Isobutylaminopyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone
 832714-85-9P, (6-Ethylaminopyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-86-0P,
 [6-(Cyclobutylamino)pyridin-3-yl] [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-87-1P,
 (6-Isopropylaminopyridin-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-88-2P,
 [6-(1-Ethylpropylamino)pyridin-3-yl] [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-91-7P,
 [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl] [6-(1-propylbutylamino)pyridin-3-yl]methanone
 832714-93-9P 832714-94-0P, (Benzoc[c]isoxazol-3-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-96-2P, (4-Chloropyridin-2-yl) [4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]methanone 832714-98-4P, 1- [4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidin-1-yl]butan-2-one
 832715-00-1P 832715-01-2P, 5'-Bromo-4- {[1- (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
 832715-02-3P, 4- {[1- (4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}-5'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
 832715-04-5P, 1- [2-Fluoro-4- (methylsulfonyl)phenyl]-4- {[1- (3-isopropyl-1,2,4-oxadiazol-5-yl)-3-pyrrolidinyl]oxy}-1H-pyrazolo[3,4-d]pyrimidine

hydrochloride 832715-07-8P, 1-[4-(Methylsulfonyl)phenyl]-4-[[1-[4-(trifluoromethoxy)phenyl]-4-piperidinyl]oxy]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride 832715-09-0P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]sulfanyl]piperidine-1-carboxylic acid isopropyl ester 832715-10-3P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-methylpyridin-3-yl)methanone 832715-11-4P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-methylpyridin-3-yl)methanone trifluoroacetate 832715-12-5P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](6-trifluoromethylpyridin-3-yl)methanone 832715-13-6P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](6-trifluoromethylpyridin-3-yl)methanone trifluoroacetate 832715-14-7P, 2-(5-Bromopyridin-3-yl)-1-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone 832715-15-8P, 2-(5-Bromopyridin-3-yl)-1-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone trifluoroacetate 832715-16-9P, (6-Fluoropyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl)methanone 832715-17-0P, (6-Fluoropyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl)methanone trifluoroacetate 832715-18-1P, (6-Chloropyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl)methanone 832715-19-2P, (6-Chloropyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl)methanone trifluoroacetate 832715-20-5P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl][5-[(2-methylpyrrolidin-1-yl)methyl]pyridin-3-yl)methanone 832715-21-6P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl][5-[(2-methylpyrrolidin-1-yl)methyl]pyridin-3-yl)methanone trifluoroacetate 832715-22-7P, 5-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]carbonyl]nicotinonitrile 832715-23-8P, 5-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]carbonyl]nicotinonitrile trifluoroacetate 832715-24-9P, 5-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]carbonyl]pyridine-2-carboxylic acid methyl ester 832715-25-0P, 5-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]carbonyl]pyridine-2-carboxylic acid methyl ester trifluoroacetate 832715-26-1P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]acetic acid ethyl ester 832715-27-2P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]acetic acid ethyl ester trifluoroacetate 832715-28-3P, 1-(4-Chlorophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone 832715-29-4P, 1-(4-Chlorophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone trifluoroacetate 832715-30-7P, 2-[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(3-trifluoromethylphenyl)ethanone 832715-31-8P, 2-[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(3-trifluoromethylphenyl)ethanone trifluoroacetate 832715-32-9P, 1-(4-Chloro-3-methylphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone 832715-33-0P, 1-(4-Chloro-3-methylphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone trifluoroacetate 832715-34-1P, 1-(3,4-Dichlorophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone 832715-35-2P, 1-(3,4-Dichlorophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone trifluoroacetate 832715-36-3P, 1-(2,4-Dimethoxyphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone 832715-37-4P, 1-(2,4-Dimethoxyphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]ethanone trifluoroacetate 832715-38-5P, 1-(4-Difluoromethoxyphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-

yl] ethanone 832715-39-6P, 1-(4-Difluoromethoxyphenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl] ethanone trifluoroacetate 832715-40-9P, 1-(4-Diethylaminophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl] ethanone 832715-41-0P, 1-(4-Diethylaminophenyl)-2-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl] ethanone trifluoroacetate 832715-42-1P, (5-Aminopyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832715-43-2P, (5-Aminopyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone trifluoroacetate 832715-44-3P, (5-Aminopyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832715-46-5P, (5-Ethylaminopyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832715-47-6P, (5-Ethylaminopyridin-2-yl)[4-[[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone trifluoroacetate 832715-48-7P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl][5-(3-methylbutylamino)pyridin-2-yl]methanone 832715-49-8P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl][5-(3-methylbutylamino)pyridin-2-yl]methanone trifluoroacetate 832715-53-4P, 4-[[1-(4-Propylaminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-54-5P, 4-[[1-(4-Isopropylaminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-55-6P, 4-[[1-[4-(Morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-56-7P, 4-[[1-(2-Fluoro-4-isopropylaminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-58-9P, 4-[[1-[2-Fluoro-4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-59-0P, 4-[[1-[4-(2-Methylsulfonylethyl)piperazin-1-yl]-2-methylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-61-4P, 4-[[1-[2-Methyl-4-[(tetrahydrofuran-2-ylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-62-5P, 4-[[1-(4-Cyclopropylamino-2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-63-6P, 4-[[1-[4-(2-Dimethylaminoethylamino)-2-methylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-64-7P, 4-[[1-[4-(2-Methylsulfonylethyl)(methyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-65-8P, 4-[[1-[4-(2-Methoxyethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-66-9P, 4-[[1-[4-[(Tetrahydrofuran-2-ylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-67-0P, 4-[[1-[4-(2-Methylsulfonylethyl)piperazin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-68-1P, 4-[[1-(4-Aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-69-2P, 4-[[1-(5-Ethylpyrimidin-2-yl)piperidin-4-ylsulfanyl]-1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 832715-70-5P, 3-tert-Butoxy-1-[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]propan-1-one 832715-71-6P, [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-3-oxopropyl(methyl)carbamic acid tert-butyl ester 832715-73-8P, trans-N-[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]cyclohexane-1,4-diamine 832715-74-9P, cis-N-[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]cyclohexyl]nicotinamide 832715-75-0P 832715-76-1P, cis-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]methyl]cyclohexyl]carbamic acid tert-butyl ester 832715-77-2P, cis-N-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]cyclohexyl]methyl]nicotinamide 832715-78-3P, cis-N-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-

yl]amino]cyclohexyl]methyl]-6-methylnicotinamide 832715-79-4P,
 4-[2-[Ethyl[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]ethyl]piperazine-1-carboxylic acid tert-butyl ester
 832715-80-7P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]isopropylamino]methyl]piperidine-1-carboxylic acid
 tert-butyl ester 832715-81-8P
 , 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]isopropylamino]methyl]piperidine-1-carboxylic acid isopropyl ester
 832715-82-9P, 4-[[1-(2-Fluoro-4-sulfamoylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832715-83-0P, (1-tert-Butyl-5-methyl-1H-pyrazol-4-yl)[4-[[1-(4-
 methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-
 yl]methanone 832715-84-1P, (5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)[4-[[1-
 (4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-
 yl]methanone 832715-85-2P, (3-Fluorophenyl)[4-[[1-(4-
 methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-
 yl]methanone 832715-87-4P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-[3-
 isopropyl-[1,2,4]oxadiazol-5-yl]methyl]piperidin-4-yl]oxy]-1H-pyrazolo[3,4-
 d]pyrimidine 832715-88-5P, 4-[[1-(4-Methylsulfonylphenyl)-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]amino]piperidine-1-carboxylic acid isopropyl
 ester 832715-90-9P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]amino]piperidine-1-carboxylic acid isobutyl ester
 832715-91-0P, [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl]amino]piperidin-1-yl](6-methylpyridin-3-yl)methanone 832715-93-2P,
 [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]piperidin-1-yl](2-methylpyridin-3-yl)methanone 832715-94-3P,
 [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]piperidin-1-yl](5-methylpyridin-3-yl)methanone 832715-95-4P,
 [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]piperidin-1-yl]pyridin-3-ylmethanone 832715-96-5P,
 [3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]piperidin-1-yl](1-methyl-1H-pyrrol-3-yl)methanone 832715-97-6P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidin-1-yl](4-trifluoromethylpyridin-3-yl)methanone
 832715-98-7P, (6-tert-Butylpyridin-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-00-4P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832716-01-5P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl](methyl)amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832716-03-7P, 3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832716-04-8P, 4-[[Ethyl[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl
 ester 832716-05-9P, 4-[[1-[2-(2-Dimethylaminoethoxy)-4-
 methylsulfonylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-
 carboxylic acid tert-butyl ester 832716-08-2P, 4-[[2-
 Dimethylaminoethyl][1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832716-11-7P, 4-[[2-Dimethylaminoethyl][1-(2-fluoro-4-
 methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832716-13-9P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]oxy]piperidin-1-yl](4-trifluoromethoxyphenyl)methanone
 832716-15-1P, [4-[[1-[3,5-Bis(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]amino]cyclohexyl]carbamic acid tert-butyl ester
 832716-17-3P, 4-[[1-[3,5-Bis(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
 832716-19-5P 832716-21-9P, 4-[[1-(3-Fluorophenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
 832716-23-1P, [4-[[1-(3-Fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]cyclohexyl]carbamic acid tert-butyl ester 832716-25-3P,
 cis-4-[[1-(2,4-Difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]cyclohexyl]carbamic acid tert-butyl ester 832716-26-4P,
 4-[[1-(2,4-Difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-
 1-carboxylic acid tert-butyl ester 832716-28-6P, trans-4-[[1-(4-

Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy)cyclohexyl]carbamic acid tert-butyl ester 832716-30-0P,
 N-[1-(2,4-Difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]cyclohexane-1,4-diamine 832716-32-2P, 4-[[1-(2,5-Difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832716-33-3P, 4-[[1-[4-(2-Methylsulfonylethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl](methyl)amino]methyl]piperidine-1-carboxylic acid tert-butyl ester 832716-35-5P, 4-[[1-(2,5-Difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl](methyl)amino]methyl]piperidine-1-carboxylic acid tert-butyl ester 832716-36-6P, 4-[[1-(2-Methyl-4-propylaminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832716-37-7P, 4-[[1-(4-Isopropylamino-2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832716-38-8P, 4-[[1-[2-Methyl-4-(morpholin-4-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832716-39-9P, 4-[[1-[4-(2-Methoxyethylamino)-2-methylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832716-41-3P, 4-[[1-[4-[(2-Methylsulfonylethyl)(methyl)amino]-2-methylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832716-42-4P, [2-4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-5-methylpyrimidin-4-yl]dimethylamine 832716-46-8P, Furan-2-yl[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-47-9P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](1-methyl-1H-pyrrol-2-yl)methanone 832716-48-0P, 2-4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(pyridin-3-yl)ethanone 832716-49-1P, 2-4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(thiophen-2-yl)ethanone 832716-50-4P, 1-4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-3,3-dimethylbutan-2-one 832716-51-5P, [4-[[1-(4-Methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](2-methylpyridin-3-yl)methanone 832716-52-6P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](6-methylpyridin-3-yl)methanone 832716-53-7P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-methylisoxazol-3-yl)methanone 832716-54-8P, 4-[[6-Dimethylamino-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832716-57-1P, 4-[[Ethyl[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylic acid isopropyl ester 832716-58-2P, 4-[[1-(2-Dimethylamino-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832716-60-6P, 4-2-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]ethyl)piperazine-1-carboxylic acid ethyl ester 832716-61-7P, 4-2-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]propyl)piperazine-1-carboxylic acid ethyl ester 832716-62-8P, (5-Fluoropyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-63-9P, (2-Chloro-5-fluoropyridin-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-64-0P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](4-methoxypyridin-2-yl)methanone 832716-65-1P, (2-Fluoropyridin-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-66-2P, (6-Fluoropyridin-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-67-3P, (4-Iodopyridin-2-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832716-68-4P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](4-methoxythiophen-3-yl)methanone 832716-70-8P, 3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]azetidine-1-carboxylic acid isopropyl ester 832716-72-0P, [4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](3-trifluoromethoxyphenyl)methanone 832716-73-1P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-

yl]oxy]piperidine-1-carboxylic acid propyl ester 832716-74-2P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid cyclohexyl ester 832716-75-3P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid tetrahydropyran-4-yl ester
 832716-76-4P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid cyclopentyl ester 832716-78-6P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid tetrahydrothiopyran-4-yl ester
 832716-79-7P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid cyclobutyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 832716-80-0P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid pyridin-3-ylmethyl ester
 832716-81-1P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid 2-(pyridin-3-yl)ethyl ester
 832716-82-2P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid 3-(pyridin-3-yl)propyl ester
 832716-83-3P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid 2-dimethylaminoethyl ester
 832716-84-4P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl](methyl)amino]piperidine-1-carboxylic acid tert-butyl ester
 832716-85-5P, 1-[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl](methyl)amino]piperidin-1-yl]-3,3-dimethylbutan-2-one
 832716-86-6P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl](methyl)amino]piperidine-1-carboxylic acid cyclobutyl ester
 832716-87-7P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]sulfanyl]piperidine-1-carboxylic acid tert-butyl ester 832716-88-8P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]sulfinyl]piperidine-1-carboxylic acid tert-butyl ester 832716-89-9P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]sulfonyl]piperidine-1-carboxylic acid tert-butyl ester 832716-90-2P,
 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]sulfonyl]piperidine-1-carboxylic acid butyl ester 832716-92-4P,
 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]sulfonyl]piperidine-1-carboxylic acid 2-methoxyethyl ester
 832716-93-5P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]sulfonyl]piperidine-1-carboxylic acid 3,3-dimethylbutyl
 ester 832716-94-6P, 4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]sulfonyl]piperidine-1-carboxylic acid
 4-methylpentyl ester 832716-95-7P, [4-[[1-(4-Methylsulfonylphenyl)-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl] [5-[(morpholin-4-
 yl)methyl]furan-2-yl]methanone 832716-96-8P, 4-[[1-(4-
 Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxyl]piperidine-1-
 carboxylic acid 2-(pyrrolidin-1-yl)ethyl ester 832716-97-9P,
 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid 2-(morpholin-4-yl)ethyl ester
 832716-98-0P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid ethyl ester 832716-99-1P,
 Ethyl[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl][(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)methyl]amine
 832717-01-8P, Ethyl[1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl][(5'-trifluoromethyl-3,4,5,6-tetrahydro-2H-
 [1,2']bipyridinyl-4-yl)methyl]amine 832717-02-9P 832717-05-2P,
 3-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]pyrrolidine-1-carboxylic acid tert-butyl ester 832717-06-3P,
 3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]pyrrolidine-1-carboxylic acid tert-butyl ester 832717-07-4P,
 3-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]amino]pyrrolidine-1-carboxylic acid isopropyl ester 832717-09-6P,

3-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]pyrrolidine-1-carboxylic acid tert-butyl ester 832717-10-9P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl][5-(pyridin-2-yl)thiophen-2-yl]methanone
 832717-11-0P, 4-[[9-(6-Methylsulfonylpyridin-3-yl)-9H-purin-6-yl]oxy]piperidine-1-carboxylic acid isobutyl ester 832717-12-1P,
 9-(6-Methylsulfonylpyridin-3-yl)-6-[(piperidin-4-yl)oxy]-9H-purine
 832717-13-2P, [4-[[9-(6-Methylsulfonylpyridin-3-yl)-9H-purin-6-yl]oxy]piperidin-1-yl]pyridin-3-ylmethanone 832717-14-3P,
 4-[[9-(4-Methylsulfonylphenyl)-9H-purin-6-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832717-17-6P, 4-[[9-(6-Methylsulfonylpyridin-3-yl)-9H-purin-6-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
 832717-19-8P, 4-[[9-(2-Fluoro-4-methylsulfonylphenyl)-9H-purin-6-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832717-20-1P,
 4-[[3-(4-Methylsulfonylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832717-30-3P,
 4-[[Ethyl[3-(4-methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidin-7-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 832717-31-4P, 4-[[3-(4-Methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidin-7-yl]sulfanyl]piperidine-1-carboxylic acid tert-butyl ester 832717-32-5P,
 4-[[3-(4-Methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-33-6P,
 4-[8-(4-Bromo-2-fluorophenyl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832717-37-0P, 4-[[8-(4-Methylsulfonylphenyl)quinolin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-39-2P,
 4-[[8-(4-Methylsulfonylphenyl)quinolin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-40-5P, 4-[8-(4-Isopropoxyphenyl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832717-41-6P,
 2-[[4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]-1-(pyridin-2-yl)ethanone 832717-42-7P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]pyrazin-2-ylmethanone 832717-43-8P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](5-methylpyrazin-2-yl)methanone 832717-44-9P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]pyrimidin-5-ylmethanone 832717-45-0P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]pyridazin-4-ylmethanone 832717-46-1P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]thiophen-2-ylmethanone 832717-47-2P,
 (3,4-Dimethylisoxazol-5-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832717-48-3P,
 [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](4-methyl-[1,2,3]thiadiazol-5-yl)methanone
 832717-49-4P, (2,5-Dimethyl-2H-pyrazol-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832717-50-7P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](3-methylisoxazol-5-yl)methanone 832717-51-8P, 4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carbothioic acid
 N-(pyridin-4-yl)amide 832717-52-9P, 3-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]piperidine-1-carboxylic acid tert-butyl ester 832717-53-0P, (2,5-Dimethylfuran-3-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832717-54-1P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)methyl]pyrrolidin-3-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine
 832717-55-2P, [4-[[1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl](6-methylpyridin-2-yl)methanone 832717-56-3P,
 (2-Fluoropyridin-4-yl)[4-[[1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidin-1-yl]methanone 832717-57-4P,
 1-(4-Methylsulfonylphenyl)-4-[[1-(4-trifluoromethoxyphenyl)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-58-5P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-[5-methyl-4-(pyrrolidin-1-yl)pyrimidin-2-yl]piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-59-6P,
 4-[[1-(2-Fluoro-4-propionylsulfamoylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-

y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-60-9P,
 4-[[1-(4-Cyano-2-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-61-0P,
 1-(2,5-Difluoro-4-methoxyphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-62-1P,
 4-[[1-(2,5-Difluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-63-2P,
 4-[[1-(4-Fluoro-6-methoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-64-3P,
 4-[[1-(6-Methoxy-2-methylpyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-65-4P,
 4-[[1-(2,5-Difluoro-4-sulfamoylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-66-5P,
 4-[[1-(2-Fluoro-4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-67-6P,
 3-Fluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-
 y1]oxy]pyrazolo[3,4-d]pyrimidin-1-yl]-N-propionylbenzenesulfonamide
 832717-68-7P, 3-Fluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]pyrazolo[3,4-d]pyrimidin-1-yl]benzonitrile
 832717-69-8P, 3-Fluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]pyrazolo[3,4-d]pyrimidin-1-yl]benzenesulfonamide
 832717-70-1P, 1-(2,5-Difluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine
 832717-71-2P, 1-(4-Fluoro-6-methoxypyridin-3-yl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine
 832717-72-3P, 4-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-(6-methoxy-2-methylpyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidine
 832717-73-4P, 2,5-Difluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]pyrazolo[3,4-d]pyrimidin-1-yl]benzenesulfonamide
 832717-74-5P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine
 832717-75-6P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]pyrazolo[3,4-d]pyrimidin-1-yl]-N-
 propionylbenzenesulfonamide 832717-76-7P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[3,4-d]pyrimidin-1-
 y1]benzonitrile 832717-77-8P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[3,4-d]pyrimidin-1-
 y1]benzenesulfonamide 832717-78-9P, 1-(2,5-Difluoro-4-
 methylsulfonylphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-79-0P,
 1-(4-Fluoro-6-methoxypyridin-3-yl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-80-3P,
 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-(6-methoxy-2-
 methylpyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidine 832717-81-4P,
 2,5-Difluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]pyrazolo[3,4-d]pyrimidin-1-yl]benzenesulfonamide
 832717-82-5P, 4-[[1-(2-Fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-83-6P,
 4-[[1-(4-Difluoromethoxy-2-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-84-7P,
 4-[[1-(2-Fluoro-4-trifluoromethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-85-8P,
 4-[[1-(2,5-Difluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832717-86-9P,
 3-Fluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-
 y1]oxy]pyrazolo[3,4-d]pyrimidin-1-yl]phenol 832717-87-0P,
 1-(2-Fluoro-4-methoxyphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-88-1P,
 1-(4-Difluoromethoxy-2-fluorophenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-89-2P,
 1-(2-Fluoro-4-trifluoromethoxyphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-90-5P,
 1-(2,5-Difluoro-4-methoxyphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)piperidin-4-yl]oxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-91-6P,
 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 y1)cyclohexyloxy]pyrazolo[3,4-d]pyrimidin-1-yl]phenol 832717-92-7P,

1-(2-Fluoro-4-methoxyphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-93-8P,
 1-(4-Difluoromethoxy-2-fluorophenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-94-9P,
 1-(2-Fluoro-4-trifluoromethoxyphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1H-pyrazolo[3,4-d]pyrimidine 832717-95-0P,
 4-[(9-(2-Fluoro-4-propionylsulfamoylphenyl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832717-96-1P, 4-[(9-(4-Cyano-2-fluorophenyl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832717-97-2P, 4-[(9-(2-Fluoro-4-sulfamoylphenyl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832717-98-3P,
 9-(2-Fluoro-4-methylsulfonylphenyl)-6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-9H-purine 832717-99-4P, 3-Fluoro-4-[6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]purin-9-yl]-N-propionylbenzenesulfonamide 832718-00-0P, 3-Fluoro-4-[6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]purin-9-yl]benzonitrile 832718-01-1P, 3-Fluoro-4-[6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]purin-9-yl]benzenesulfonamide 832718-02-2P,
 4-[(9-(2,5-Difluoro-4-methylsulfonylphenyl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-03-3P, 4-[(9-(4-Fluoro-6-methoxypyridin-3-yl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-04-4P, 4-[(9-(6-Methoxy-2-methylpyridin-3-yl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-05-5P, 4-[(9-(2,5-Difluoro-4-sulfamoylphenyl)-9H-purin-6-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-06-6P,
 9-(2,5-Difluoro-4-methylsulfonylphenyl)-6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-9H-purine 832718-07-7P, 9-(4-Fluoro-6-methoxypyridin-3-yl)-6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-9H-purine 832718-08-8P, 6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-9-(6-methoxy-2-methylpyridin-3-yl)-9H-purine 832718-09-9P, 2,5-Difluoro-4-[6-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]purin-9-yl]benzenesulfonamide 832718-10-2P, 9-(2-Fluoro-4-methylsulfonylphenyl)-6-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-9H-purine 832718-11-3P,
 3-Fluoro-4-[6-[(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]purin-9-yl]-N-propionylbenzenesulfonamide 832718-12-4P, 3-Fluoro-4-[6-[(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]purin-9-yl]benzonitrile 832718-13-5P, 3-Fluoro-4-[6-[(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]purin-9-yl]benzenesulfonamide 832718-14-6P,
 9-(2,5-Difluoro-4-methylsulfonylphenyl)-6-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-9H-purine 832718-15-7P,
 9-(4-Fluoro-6-methoxypyridin-3-yl)-6-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-9H-purine 832718-16-8P, 6-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-9-(6-methoxy-2-methylpyridin-3-yl)-9H-purine 832718-17-9P, 2,5-Difluoro-4-[6-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)purin-9-yl]benzenesulfonamide 832718-18-0P,
 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-19-1P, 3-Fluoro-4-[7-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-20-4P, 3-Fluoro-4-[7-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzonitrile 832718-21-5P, 3-Fluoro-4-[7-[(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-22-6P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-23-7P, 3-Fluoro-4-[7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-24-8P,
 3-Fluoro-4-[7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzonitrile 832718-25-9P, 3-Fluoro-4-[7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-26-0P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-27-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[(4-(3-isopropyl-[1,2,4]oxadiazol-5-

yl)cyclohexyloxy]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-28-2P,
 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-29-3P,
 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-30-6P,
 4-[(3-(2-Fluoro-4-methylsulfonylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-31-7P,
 4-[(3-(2-Fluoro-4-propionylsulfamoylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-32-8P,
 4-[[3-(4-Cyano-2-fluorophenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-33-9P,
 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-34-0P,
 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-35-1P,
 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-36-2P,
 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-37-3P,
 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-38-4P,
 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-39-5P,
 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-40-8P,
 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832718-41-9P,
 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzenesulfonamide 832718-42-0P,
 4-[[8-(2-Fluoro-4-methylsulfonylphenyl)-[1,7]naphthyridin-4-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-43-1P,
 4-[[8-(2-Fluoro-4-methylsulfonylphenyl)quinolin-4-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-44-2P,
 4-[[8-(2-Fluoro-4-propionylsulfamoylphenyl)quinolin-4-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-45-3P,
 4-[[8-(4-Cyano-2-fluorophenyl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832718-46-4P,
 4-[[8-(2-Fluoro-4-sulfamoylphenyl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832718-47-5P,
 4-[[8-(2,5-Difluoro-4-methylsulfonylphenyl)quinolin-4-yl)oxy]piperidine-1-carboxylic acid isopropyl ester 832718-48-6P,
 4-[[8-(4-Fluoro-6-methoxypyridin-3-yl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832718-49-7P,
 4-[[8-(6-Methoxy-2-methylpyridin-3-yl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832718-50-0P,
 4-[[8-(2,5-Difluoro-4-sulfamoylphenyl)quinolin-4-yloxy]piperidine-1-carboxylic acid isopropyl ester 832718-51-1P
 , 2,5-Difluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]benzenesulfonamide 832718-52-2P,
 4-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]-8-(6-methoxy-2-methylpyridin-3-yl)quinoline 832718-53-3P,
 8-(4-Fluoro-6-methoxypyridin-3-yl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]quinoline 832718-54-4P,
 8-(2,5-Difluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]quinoline 832718-55-5P,
 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]benzenesulfonamide 832718-56-6P,
 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]quinolin-8-yl]benzonitrile 832718-57-7P,
 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]quinolin-8-yl]-N-propionylbenzenesulfonamide 832718-58-8P,
 8-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)oxy]quinoline 832718-59-9P,
 2,5-Difluoro-4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]benzenesulfonamide 832718-60-2P,
 4-[[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]-8-(6-methoxy-2-methylpyridin-3-yl)quinoline 832718-61-3P,
 8-(4-Fluoro-6-methoxypyridin-3-yl)-4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]-8-(2,5-Difluoro-4-cyclohexyloxy)quinoline 832718-62-4P

methylsulfonylphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinoline 832718-63-5P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]benzenesulfonamide 832718-65-7P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]benzonitrile 832718-67-9P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinolin-8-yl]-N-propionylbenzenesulfonamide 832718-68-0P, 8-(2-Fluoro-4-methylsulfonylphenyl)-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]quinoline 832718-69-1P, 4-[[8-(2-Fluoro-4-methylsulfonylphenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-70-4P, 4-[[8-(2-Fluoro-4-propionylsulfonylphenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-72-6P, 4-[[8-(4-Cyano-2-fluorophenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-74-8P, 4-[[8-(2-Fluoro-4-sulfamoylphenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-75-9P, 4-[[8-(2,5-Difluoro-4-methylsulfonylphenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-76-0P, 4-[[8-(4-Fluoro-6-methoxypyridin-3-yl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-77-1P, 4-[[8-(6-Methoxy-2-methylpyridin-3-yl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-78-2P, 4-[[8-(2,5-Difluoro-4-sulfamoylphenyl)pyrido[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832718-79-3P, 8-(2-Fluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrido[3,4-d]pyrimidine 832718-80-6P, 3-Fluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrido[3,4-d]pyrimidin-8-yl]benzenesulfonamide 832718-83-9P, 8-(2,5-Difluoro-4-methylsulfonylphenyl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrido[3,4-d]pyrimidine 832718-84-0P, 8-(4-Fluoro-6-methoxypyridin-3-yl)-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrido[3,4-d]pyrimidine 832718-85-1P, 4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-8-(6-methoxy-2-methylpyridin-3-yl)pyrido[3,4-d]pyrimidine 832718-86-2P, 2,5-Difluoro-4-[4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrido[3,4-d]pyrimidin-8-yl]benzenesulfonamide 832718-87-3P, 8-(2-Fluoro-4-methylsulfonylphenyl)-4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidine 832718-88-4P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidin-8-yl]-N-propionylbenzenesulfonamide 832718-89-5P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidin-8-yl]benzonitrile 832718-90-8P, 3-Fluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidin-8-yl]benzenesulfonamide 832718-91-9P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidine 832718-92-0P, 8-(4-Fluoro-6-methoxypyridin-3-yl)-4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidine 832718-93-1P, 4-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-8-(6-methoxy-2-methylpyridin-3-yl)pyrido[3,4-d]pyrimidine 832718-94-2P, 2,5-Difluoro-4-[4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrido[3,4-d]pyrimidin-8-yl]benzenesulfonamide 832718-95-3P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832718-96-4P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832718-98-6P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-]

y1]benzenesulfonamide 832718-99-7P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-y1)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-00-3P, 3-(4-Fluoro-6-methoxypyridin-3-y1)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-y1)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-01-4P, 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-y1)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-y1)pyrazolo[1,5-a]pyrimidine 832719-02-5P, 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-y1)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-y1]benzenesulfonamide 832719-03-6P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-04-7P, 4-[[3-(2-Fluoro-4-propionylsulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-05-8P, 4-[[3-(4-Cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-06-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-07-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-08-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-y1)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-09-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-y1)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-10-5P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-11-6P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 832719-12-7P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidin-3-y1]-N-propionylbenzenesulfonamide 832719-13-8P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidin-3-y1]benzonitrile 832719-14-9P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidin-3-y1]benzenesulfonamide 832719-15-0P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidine 832719-16-1P, 3-(4-Fluoro-6-methoxypyridin-3-y1)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidine 832719-17-2P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]-3-(6-methoxy-2-methylpyridin-3-y1)pyrazolo[1,5-a]pyrimidine 832719-18-3P, 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-y1)piperidin-4-y1]oxy]pyrazolo[1,5-a]pyrimidin-3-y1]benzenesulfonamide 832719-19-4P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-20-7P, 4-[[3-(2-Fluoro-4-propionylsulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-21-8P, 4-[[3-(4-Cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-22-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-23-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-24-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-y1)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-25-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-y1)-2-methylpyrazolo[1,5-a]pyrimidin-7-y1]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-26-3P

, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-27-4P
 , 2,5-Difluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide
 832719-28-5P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-29-6P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-30-9P,
 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-31-0P, 3-Fluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-32-1P, 3-Fluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-33-2P, 3-Fluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-34-3P,
 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-35-4P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-36-5P, 3-Fluoro-4-[[7-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-37-6P,
 3-Fluoro-4-[[7-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-38-7P,
 3-Fluoro-4-[[7-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-39-8P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-40-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-41-2P, 7-[[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-42-3P, 2,5-Difluoro-4-[[7-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-43-4P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-44-5P,
 4-[[3-(2-Fluoro-4-propionylsulfonylphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-45-6P, 4-[[3-(4-Cyano-2-fluorophenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-46-7P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-47-8P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-49-0P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-50-3P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-52-5P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-54-7P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-56-9P,
 3-Fluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzonitrile 832719-57-0P,
 3-Fluoro-4-[[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-58-1P,
 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-59-2P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-

isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-60-5P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-61-6P, 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-62-7P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-63-8P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzonitrile 832719-65-0P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-66-1P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-67-2P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-68-3P, 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 832719-69-4P, 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-70-7P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-71-8P, 4-[[3-(2-Fluoro-4-propionylsulfonylphenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-72-9P, 4-[[3-(4-Cyano-2-fluorophenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-73-0P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-74-1P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-75-2P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-76-3P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-77-4P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-78-5P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-79-6P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-80-9P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzonitrile 832719-81-0P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-82-1P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-83-2P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-84-3P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-85-4P, 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-86-5P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-87-6P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]-oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzonitrile 832719-88-7P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-89-8P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl]benzenesulfonamide 832719-90-1P, 3-(2,5-Difluoro-4-

methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-91-2P,
 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-92-3P,
 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 832719-93-4P
 832721-29-6P 832721-30-9P 832721-31-0P 832721-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 35613-84-4P, N-Hydroxyisobutyramidine 49713-38-4P, 2-[(2-Iodophenylamino)methylene]malonic acid diethyl ester 49713-55-5P,
 4-Chloro-8-iodoquinoline 51075-37-7P, 1-Cyano-4-hydroxypiperidine 56029-45-9P, 6-tert-Butylnicotinonitrile 106368-32-5P,
 5-Amino-1-(4-methylsulfonylphenyl)-1H-pyrazole-4-carbonitrile 138022-02-3P, 4-[(Methylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 149806-52-0P, 5'-Bromo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-ol 155456-32-9P, 4-[(Acetylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 205597-70-2P, 8-Iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 329776-71-8P,
 4-Methylsulfonylbenzoic acid phenyl ester 606126-17-4P,
 3-Fluoro-4-hydrazinobenzenesulfonamide 614745-80-1P,
 4-[(Ethylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 681508-69-0P, 4-Hydroxy-1-(4-trifluoromethoxyphenyl)piperidine 832714-07-5P, 1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 832714-08-6P, 4-Chloro-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 832714-10-0P, 5-Amino-1-(4-methylsulfonylphenyl)-3-methyl-1H-pyrazole-4-carbonitrile 832714-11-1P, 1-(4-Methylsulfonylphenyl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol 832714-12-2P,
 4-Chloro-1-(4-methylsulfonylphenyl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidine 832714-14-4P, N-[4-Cyano-2-(4-methylsulfonylphenyl)-5-methyl-2H-pyrazol-3-yl]acetamide 832714-15-5P, 1-(4-Methylsulfonylphenyl)-3,6-dimethyl-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one 832714-16-6P, 4-Chloro-1-(4-methylsulfonylphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidine 832714-37-1P, 1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ol 832714-38-2P, 4-Chloro-1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 832714-47-3P, 5-Amino-1-(2-fluoro-4-methylsulfonylphenyl)-1H-pyrazole-4-carbonitrile 832714-49-5P, 1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 832714-56-4P,
 5-Isopropoxymethylpyridine-2-carbonitrile 832714-58-6P,
 5-Isopropoxymethylpyridine-2-carboxylic acid 832714-60-0P,
 5-Isopropoxypyridine-2-carboxylic acid 832715-03-4P,
 5'-Trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-ol 832715-05-6P, 3-Hydroxy-1-[(3-isopropyl-1,2,4-oxadiazol-5-yl)methyl]pyrrolidine 832715-89-6P, [1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl](piperidin-4-yl)amine 832715-92-1P,
 [1-(4-Methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl](piperidin-3-yl)amine 832715-99-8P, 6-tert-Butylnicotinic acid 832716-06-0P,
 1-[2-(2-Dimethylaminoethoxy)-4-methylsulfonylphenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-ol 832716-07-1P, [2-[2-(4-Chloropyrazolo[3,4-d]pyrimidin-1-yl)-5-methylsulfonylphenoxy]ethyl]dimethylamine 832716-09-3P,
 4-(2-Dimethylaminoethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 832716-10-6P, 4-[(2-Dimethylaminoethylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 832716-55-9P 832716-56-0P,
 [4-Chloro-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]dimethylamine 832716-59-3P, 1-(2-Dimethylamino-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 832716-71-9P,
 4-(Azetidin-3-yloxy)-1-(4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 832716-91-3P, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[(piperidin-4-yl)sulfanyl]-1H-pyrazolo[3,4-d]pyrimidine 832717-15-4P,
 4-[[5-Amino-6-[(4-methylsulfonylphenyl)amino]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 832717-21-2P, 7-Chloro-3-(4-

methylsulfonylphenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 832717-23-4P,
 1-(4-Methylsulfonylphenyl)-2-nitroethanone 832717-24-5P,
 1-(4-Methylsulfonylphenyl)-2-nitroethanone oxime 832717-25-6P,
 3-(4-Methylsulfonylphenyl)-4-nitroisoxazole-5-carboxylic acid ethyl ester
 832717-26-7P, 4-Amino-3-(4-methylsulfonylphenyl)isoxazole-5-carboxylic
 acid ethyl ester 832717-27-8P, 4-Amino-3-(4-
 methylsulfonylphenyl)isoxazole-5-carboxamide 832717-28-9P,
 3-(4-Methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidin-7-ol 832717-29-0P,
 7-Chloro-3-(4-methylsulfonylphenyl)isoxazolo[4,5-d]pyrimidine
 832717-34-7P, 8-Iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
 832717-35-8P, 8-Iodo-1H-quinolin-4-one 832717-36-9P,
 8-(4-Bromo-2-fluorophenyl)-4-chloroquinoline 832717-38-1P,
 4-(8-Chloroquinolin-4-yloxy)piperidine-1-carboxylic acid isopropyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)

IT 71-41-0, n-Pentanol, reactions 78-82-0, Isobutyronitrile 87-13-8
 97-95-0, 2-Ethylbutan-1-ol 100-54-9, 3-Cyanopyridine 108-00-9,
 N,N-Dimethyl-1,2-ethylenediamine 108-01-0, 2-(Dimethylamino)ethanol
 108-23-6, Isopropyl chloroformate 109-04-6, 2-Bromopyridine 123-06-8
 407-14-7, 4-(Trifluoromethoxy)bromobenzene 535-89-7,
 (2-Chloro-6-methylpyrimidin-4-yl)dimethylamine 536-69-6,
 5-Butylpyridine-2-carboxylic acid 543-27-1, Isobutyl chloroformate
 584-02-1, 3-Pentanol 585-70-6, 5-Bromofuran-2-carboxylic acid
 592-34-7, n-Butyl chloroformate 615-43-0, 2-Iodoaniline 816-40-0,
 Bromomethyl ethyl ketone 1462-86-8, 3-Aminopicolinic acid 2516-33-8,
 Cyclopropylmethanol 2566-44-1, 2-Cyclopropylethanol 3637-61-4,
 Cyclopentylmethanol 4021-13-0, 4-Ethylpyridine-2-carboxylic acid
 4052-30-6, 4-Methylsulfonylbenzoic acid 4415-82-1, Cyclobutylmethanol
 4755-77-5, 1-(Chlorocarbonyl)formic acid ethyl ester 4837-20-1,
 4-Difluoromethoxybenzoic acid 5326-23-8, 6-Chloronicotinic acid
 5382-16-1, 4-Hydroxypiperidine 5417-82-3, 1-
 Ethoxyethylidenemalononitrile 16331-46-7, 4-Ethoxybenzoyl chloride
 17852-67-4, 4-(Methylsulfonyl)phenylhydrazine hydrochloride 20260-53-1,
 Nicotinoyl chloride hydrochloride 20412-38-8, Neopentyl chloroformate
 21617-12-9, 4,8-Dichloroquinoline 26095-36-3, 5-[(Morpholin-4-
 yl)methyl]furan-2-carboxylic acid 36823-88-8, 4-Trifluoromethoxybenzoyl
 chloride 40499-83-0, 3-Hydroxypyrrrolidine 50488-42-1,
 2-Bromo-5-trifluoromethylpyridine 52334-81-3, 5-Trifluoromethyl-2-
 chloropyridine 53939-30-3, 5-Bromo-2-chloropyridine 54042-97-6,
 5-Chloromethyl-3-isopropyl-[1,2,4]oxadiazole 84358-13-4,
 1-tert-Butoxycarbonylisopropionic acid 98546-51-1, (4-
 Methylthiophenyl)boronic acid 103057-44-9, 3-Hydroxypyrrrolidine-1-
 carboxylic acid tert-butyl ester 103962-10-3, 2-Bromo-1-(4-
 trifluoromethoxyphenyl)ethanone 108966-71-8, 3,4-
 Difluorobenesulfonamide 109384-19-2, 4-Hydroxypiperidine-1-carboxylic
 acid tert-butyl ester 111196-81-7, 2-Chloro-5-ethylpyrimidine
 134464-79-2, 4-Mercaptopiperidine-1-carboxylic acid tert-butyl ester
 144222-22-0, 4-Aminomethylpiperidine-1-carboxylic acid tert-butyl ester
 153624-46-5, 4-Isopropoxyphenylboronic acid 175205-81-9,
 2-Bromo-4-trifluoromethylpyridine 195314-59-1, (4-
 Aminocyclohexyl)carbamic acid tert-butyl ester 223382-13-6,
 1-Benzylazetidin-3-ol hydrochloride 479065-30-0, 1-(2-
 Methylsulfonylethyl)piperazine 733751-06-9, (6-Chloro-5-nitropyrimidin-4-
 yl)(4-methylsulfonylphenyl)amine 832714-22-4, 1-(4-Methylsulfonylphenyl)-
 4-[(piperidin-4-yl)oxy]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride
 832714-24-6, 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[(piperidin-4-
 yl)sulfanyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride 832714-35-9,
 1-(2-Fluoro-4-methylsulfonylphenyl)-4-[(piperidin-4-yl)oxy]-1H-
 pyrazolo[3,4-d]pyrimidine hydrochloride 832714-48-4,
 (2-Fluoro-4-methylsulfonylphenyl)hydrazine 832714-57-5,
 2-Chloro-5-(isopropoxymethyl)pyridine 832714-62-2, 5'-Isopropoxy-3,4,5,6-
 tetrahydro-2H-[1,2']bipyridinyl-4-ol 832714-73-5 832715-51-2,

4-Hydroxypiperidine-1-carboxylic acid isopropyl ester 832715-52-3,
 1-(4-Bromophenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine 832715-57-8,
 4-[[1-(2-Fluoro-4-iodophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-60-3,
 4-[[1-(4-Iodo-2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832715-86-3,
 (3-Fluorophenyl)(4-hydroxypiperidin-1-yl)methanone 832716-16-2,
 1-[3,5-Bis(trifluoromethyl)phenyl]-4-chloro-1H-pyrazolo[3,4-d]pyrimidine
 832717-00-7 832717-04-1, [1-[(3-Isopropyl-[1,2,4]oxadiazol-5-
 yl)methyl]pyrrolidin-3-yl]amine 832717-08-5, [1-(2-Fluoro-4-
 methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl](pyrrolidin-3-
 yl)amine 832717-16-5, 4-[[6-[(4-Methylsulfonylphenyl)amino]-5-
 nitropyrimidin-4-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
 832717-18-7, 4-[[5-Amino-6-(6-methylsulfonylpiperidin-3-ylamino)pyrimidin-4-
 yl]oxy]piperidine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of fused aryl and heteroaryl derivs., in particular
 pyrazolopyrimidines, as modulators of G-coupled protein receptor and
 their use in treatment of diabetes, hyperglycemia and related diseases)

IT 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; preparation of fused aryl and heteroaryl derivs., in particular
 pyrazolopyrimidines, as modulators of G-coupled protein receptor and
 their use in treatment of diabetes, hyperglycemia and related diseases)

IT 50-99-7, D-Glucose, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tolerance; preparation of fused aryl and heteroaryl derivs., in particular
 pyrazolopyrimidines, as modulators of G-coupled protein receptor and
 their use in treatment of diabetes, hyperglycemia and related diseases)

IT 833495-62-8 833495-64-0 833495-65-1 833495-66-2 833495-67-3
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; preparation of fused aryl and heteroaryl
 derivs., in particular pyrazolo[3,4-d]pyrimidines, as modulators of
 G-coupled protein receptor and their use in the prophylaxis and
 treatment of metabolic disorders)

IT 833495-63-9
 RL: PRP (Properties)
 (unclaimed protein sequence; preparation of fused aryl and heteroaryl
 derivs., in particular pyrazolo[3,4-d]pyrimidines, as modulators of
 G-coupled protein receptor and their use in the prophylaxis and
 treatment of metabolic disorders)

IT 754986-47-5
 RL: PRP (Properties)
 (unclaimed sequence; preparation of fused aryl and heteroaryl derivs., in
 particular pyrazolo[3,4-d]pyrimidines, as modulators of G-coupled
 protein receptor and their use in the prophylaxis and treatment of
 metabolic disorders)

IT 832718-95-3P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-
 isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine
 832718-96-4P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]-N-
 propionylbenzenesulfonamide 832718-97-5P, 3-Fluoro-4-[7-[4-(3-
 isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-
 yl]benzonitrile 832718-98-6P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-
 yl]benzenesulfonamide 832718-99-7P, 3-(2,5-Difluoro-4-
 methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-00-3P,
 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-01-4P,
 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-
 methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine 832719-02-5P,
 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-
 yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide
 832719-03-6P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-
 a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester

832719-04-7P, 4-[[3-(2-Fluoro-4-propionylsulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-05-8P, 4-[[3-(4-Cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-06-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-07-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-08-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-09-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-10-5P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-11-6P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidine 832719-12-7P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-ylbenzenesulfonamide 832719-13-8P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-ylbenzonitrile 832719-14-9P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-ylbenzenesulfonamide 832719-15-0P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidine 832719-16-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidine 832719-17-2P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine 832719-18-3P, 2,5-Difluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-ylbenzenesulfonamide 832719-19-4P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-20-7P, 4-[[3-(2-Fluoro-4-propionylsulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-21-8P, 4-[[3-(4-Cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
 832719-22-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-23-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-24-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-25-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-26-3P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-27-4P, 2,5-Difluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-ylbenzenesulfonamide 832719-28-5P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-29-6P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-30-9P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-31-0P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-ylbenzenesulfonamide 832719-32-1P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-ylbenzonitrile 832719-33-2P, 3-Fluoro-4-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl-N-propionylbenzenesulfonamide 832719-34-3P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)


yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine
 832719-35-4P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-36-5P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-37-6P,
 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-38-7P,
 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide
 832719-39-8P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-40-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-41-2P, 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-42-3P, 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in treatment of diabetes, hyperglycemia and related diseases)


RN 832718-95-3 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832718-96-4 HCPLUS

CN Propanamide, N-[[3-fluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832718-97-5 HCPLUS

CN Benzonitrile, 3-fluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832718-98-6 HCPLUS

CN Benzenesulfonamide, 3-fluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832718-99-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-00-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-fluoro-6-methoxy-3-pyridinyl)-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-01-4 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(6-methoxy-2-methyl-3-pyridinyl)-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-02-5 HCPLUS

CN Benzenesulfonamide, 2,5-difluoro-4-[[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-03-6 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-[2-fluoro-4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-04-7 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-[2-fluoro-4-[(1-oxopropyl)amino]sulfonyl]phenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-05-8 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-(4-cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl)oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-06-9 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-[4-(aminosulfonyl)-2-fluorophenyl]pyrazolo[1,5-a]pyrimidin-7-yl)oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-07-0 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[2,5-difluoro-4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-08-1 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-fluoro-6-methoxy-3-pyridinyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-09-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-(6-methoxy-2-methyl-3-pyridinyl)pyrazolo[1,5-a]pyrimidin-7-yl)oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)


RN 832719-10-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-[4-(aminosulfonyl)-2,5-difluorophenyl]pyrazolo[1,5-a]pyrimidin-7-yl)oxy]-, 1-methylethyl ester
(9CI) (CA INDEX NAME)




RN 832719-11-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-12-7 HCPLUS

CN Propanamide, N-[[3-fluoro-4-[7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832719-13-8 HCPLUS

CN Benzonitrile, 3-fluoro-4-[(7-[(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl)oxy]pyrazolo[1,5-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)




RN 832719-14-9 HCPLUS

CN Benzenesulfonamide, 3-fluoro-4-[(7-[(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl)oxy]pyrazolo[1,5-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)





RN 832719-15-0 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-7-[(1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 832719-16-1 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-(4-fluoro-6-methoxy-3-pyridinyl)-7-[(1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)






RN 832719-19-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-20-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-[(1-oxopropyl)amino]sulfonyl]phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-21-8 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(4-cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-22-9 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[4-(aminosulfonyl)-2-fluorophenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-23-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)


RN 832719-24-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-fluoro-6-methoxy-3-pyridinyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-25-2 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(6-methoxy-2-methyl-3-pyridinyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-26-3 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[4-(aminosulfonyl)-2,5-difluorophenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-27-4 HCAPLUS

CN Benzenesulfonamide, 2,5-difluoro-4- [2-methyl-7- [[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl] - (9CI) (CA INDEX NAME)




RN 832719-28-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-7- [[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy] - (9CI) (CA INDEX NAME)




RN 832719-29-6 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[(4-fluoro-6-methoxy-3-pyridinyl)-2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI)
(CA INDEX NAME)




RN 832719-30-9 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[(2,5-difluoro-4-(methylsulfonyl)phenyl)-2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI)
(CA INDEX NAME)




RN 832719-31-0 HCPLUS

CN Benzenesulfonamide, 3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)




RN 832719-32-1 HCPLUS

CN Benzonitrile, 3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)




RN 832719-33-2 HCAPLUS

CN Propanamide, N-[[3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832719-34-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-35-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[(4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]- (9CI) (CA INDEX NAME)




RN 832719-36-5 HCAPLUS

CN Propanamide, N-[(3-fluoro-4-[2-methyl-7-[(4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 832719-37-6 HCPLUS

CN Benzonitrile, 3-fluoro-4-[2-methyl-7-[(4-[(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-38-7 HCPLUS

CN Benzenesulfonamide, 3-fluoro-4-[2-methyl-7-[(4-[(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-39-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-40-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-fluoro-6-methoxy-3-pyridinyl)-2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-41-2 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-7-[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-42-3 HCPLUS

CN Benzenesulfonamide, 2,5-difluoro-4-[2-methyl-7-[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)



L24 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:523288 HCAPLUS
 DN 141:225452
 ED Entered STN: 30 Jun 2004
 TI Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists
 AU Huang, Charles Q.; Wilcoxen, Keith M.; Grigoriadis, Dimitri E.; McCarthy, James R.; Chen, Chen
 CS Department of Medicinal Chemistry and Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, CA, 92129, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(15), 3943-3947
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 22
 OS CASREACT 141:225452
 GI



AB A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R1 = Cl, O2N, Me, F3C, H2N, HO, etc.; R2 = H, Me, Cl, O2N, H2N, MeO, NO, etc.; R3, R4 = n-Pr, n-Bu, MeOCH2CH2, cyclopropylmethyl, PhCH2] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF1) receptor. Several compds. such as I [R1 = Me2N; R2 = Me; R3 = R4 = n-Pr;

(III)] ($K_i = 10 \text{ nM}$) exhibited good binding affinities at the CRF1 receptor. In addition, II had adequate solubility in water.

ST pyrazolopyrimidine pyridyl prepn corticotropin released factor receptor antagonist lipophilicity

IT Human

Lipophilicity
(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT Structure-activity relationship
(receptor-binding; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT Corticotropin releasing factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type I; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 157284-96-3, Antalarmin 184241-44-9, NBI 27914 195054-99-0, NBI 30545
202578-52-7, DMP 696 202579-74-6, DMP 904 226948-11-4, CRA 1000
321839-75-2, SSR 125543A 388122-48-3, CRA 0450 745822-16-6, CP 142526
RL: PRP (Properties)
(calculated lipophilicity of corticotropin-releasing factor receptor antagonists)

IT 111-92-2, Dibutylamine 111-95-5 142-84-7, Dipropylamine 2032-33-9,
Benzyl(propyl)amine 20193-21-9, (Butyl)propylamine 26389-60-6,
(Cyclopropylmethyl)propylamine 43175-57-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(chloropyrimidine amination; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 141-97-9, Ethyl acetoacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(heterocyclization; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 111-30-8, Pentanodial 157764-10-8
RL: MSC (Miscellaneous)
(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 195055-07-3P 195055-09-5P 195055-72-2P 195055-73-3P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 195055-05-1P 195055-11-9P 195055-68-6P 195055-69-7P 195055-70-0P
195055-71-1P 195055-74-4P 195055-75-5P 195055-76-6P
195055-84-6P 195055-95-9P 195055-96-0P 195055-97-1P 195055-98-2P
195055-99-3P 195056-00-9P 195056-01-0P 744210-28-4P 744210-29-5P
744210-30-8P 744210-31-9P 744210-32-0P 744210-35-3P 744210-36-4P
744210-37-5P 744210-38-6P 744210-39-7P 744210-40-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 16063-70-0, 2,3,5-Trichloropyridine 16110-09-1, 2,5-Dichloropyridine
22280-56-4 23056-40-8 69045-84-7, 2,3-Dichloro-5-(trifluoromethyl)pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 744209-92-5P 744209-93-6P 744209-95-8P 744209-96-9P 744209-97-0P
744209-98-1P 744210-00-2P 744210-01-3P 744210-03-5P 744210-05-7P
744210-07-9P 744210-09-1P 744210-11-5P 744210-14-8P 744210-16-0P
744210-18-2P 744210-20-6P 744210-23-9P 744210-26-2P 744210-27-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)


IT 1116-98-9, tert-Butyl cyanoacetate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (pyridine alkylation; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 5765-44-6, 5-Methylisoxazole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (ring opening; preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

IT 195055-71-1P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of (pyridyl)pyrazolopyrimidines as corticotropin-releasing factor receptor antagonists and their calculated lipophilicity)

RN 195055-71-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:875291 HCAPLUS
 DN 139:350751
 ED Entered STN: 07 Nov 2003
 TI Preparation of pyrazolo[1,5-a]pyrimidine derivatives as NAD(P)H oxidase inhibitors
 IN Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki; Fujishita, Toshio
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 240 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM C07D487-04
 ICS A61K031-519; A61K031-5377; A61P009-00; A61P009-10; A61P009-12;
 A61P011-00; A61P027-02; A61P029-00; A61P043-00
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003091256	A1	20031106	WO 2003-JP5024	20030418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2483306 AA 20031106 CA 2003-2483306 20030418
 EP 1505068 A1 20050209 EP 2003-717663 20030418
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003009475 A 20050301 BR 2003-9475 20030418
 PRAI JP 2002-121519 A 20020423
 WO 2003-JP5024 W 20030418

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003091256	ICM	C07D487-04
	ICS	A61K031-519; A61K031-5377; A61P009-00; A61P009-10; A61P009-12; A61P011-00; A61P027-02; A61P029-00; A61P043-00
WO 2003091256	ECLA	A61K031/519; A61K031/5377; C07D487/04+239C+231C
EP 1505068	ECLA	A61K031/519; A61K031/5377; C07D487/04+239C+231C
OS MARPAT 139:350751		
GI		



AB Title compds. I (R1, R2, R3, R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, , aryl, heteroaryl, etc.) and their pharmaceutically acceptable salts, useful in the prevention of or treatments for diseases relating to NAD(P)H, are prepared. Thus, N-2-cyclohexylphenyl 3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amide was prepared in several steps from Et 7-chloropyrazolo[1,5-a]pyrimidine-5-carboxylate.

ST pyrazolopyrimidine prepn NADH NADPH oxidase inhibitor

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Ischemia
 (cardiac; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Lung, disease
 (circulation; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Diabetes mellitus
 (complication; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Eye, disease
 (diabetic retinopathy; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Brain, disease
 (infarction; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Heart, disease
 (ischemia; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Anti-inflammatory agents
 Antidiabetic agents
 Antihypertensives
 Atherosclerosis
 Human
 Hypertension

Inflammation

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT Brain, disease

(vascular; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT 9032-21-7, NADH oxidase 77106-92-4, NAD(P)H oxidase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT	619305-38-3	619305-39-4	619305-40-7	619305-41-8	619305-42-9
	619305-43-0	619305-44-1	619305-45-2	619305-46-3	619305-47-4
	619305-48-5	619305-49-6	619305-50-9	619305-51-0	619305-52-1
	619305-53-2	619305-54-3	619305-55-4	619305-56-5	619305-57-6
	619305-58-7	619305-59-8	619305-60-1	619305-61-2	619305-62-3
	619305-63-4	619305-64-5	619305-65-6	619305-66-7	619305-67-8
	619305-68-9	619305-69-0	619305-70-3	619305-71-4	619305-72-5
	619305-73-6	619305-74-7	619305-75-8	619305-76-9	619305-77-0
	619305-78-1	619305-79-2	619305-80-5	619305-81-6	619305-82-7
	619305-83-8	619305-84-9	619305-85-0	619305-86-1	619305-87-2
	619305-88-3	619305-89-4	619305-90-7	619305-91-8	619305-92-9
	619305-93-0	619305-94-1	619305-95-2	619305-96-3	619305-97-4
	619305-98-5	619305-99-6	619306-00-2	619306-01-3	619306-02-4
	619306-03-5	619306-04-6	619306-05-7	619306-06-8	619306-07-9
	619306-08-0	619306-09-1	619306-10-4	619306-11-5	619306-12-6
	619306-13-7	619306-14-8	619306-15-9	619306-16-0	619306-17-1
	619306-18-2	619306-19-3	619306-20-6	619306-21-7	619306-22-8
	619306-23-9	619306-24-0	619306-25-1	619306-26-2	619306-27-3
	619306-28-4	619306-29-5	619306-30-8	619306-31-9	
	619306-32-0	619306-33-1	619306-34-2	619306-35-3	
	619306-36-4	619306-37-5	619306-38-6	619306-39-7	
	619306-40-0	619306-41-1	619306-42-2	619306-43-3	619306-44-4
	619306-45-5	619306-46-6	619306-47-7	619306-48-8	619306-49-9
	619306-50-2	619306-51-3	619306-52-4	619306-53-5	619306-54-6
	619306-55-7	619306-56-8	619306-57-9	619306-58-0	619306-59-1
	619306-60-4	619306-61-5	619306-62-6	619306-63-7	619306-64-8
	619306-65-9	619306-66-0	619306-67-1	619306-68-2	619306-69-3
	619306-70-6	619306-71-7	619306-72-8	619306-73-9	619306-74-0
	619306-75-1	619306-76-2	619306-77-3	619306-78-4	619306-79-5
	619306-80-8	619306-81-9			

RL: PAC (Pharmacological activity); BIOL (Biological study)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT	619302-82-8P	619302-85-1P	619302-88-4P	619302-89-5P	619302-92-0P
	619302-95-3P	619302-98-6P	619303-00-3P	619303-04-7P	619303-08-1P
	619303-12-7P	619303-16-1P	619303-22-9P	619303-26-3P	619303-29-6P
	619303-33-2P	619303-36-5P	619303-38-7P	619303-39-8P	619303-40-1P
	619303-41-2P	619303-44-5P	619303-48-9P	619303-52-5P	619303-56-9P
	619303-59-2P	619303-63-8P	619303-65-0P	619303-67-2P	619303-69-4P
	619303-71-8P	619303-73-0P	619303-74-1P	619303-75-2P	619303-77-4P
	619303-79-6P	619303-81-0P	619303-83-2P	619303-85-4P	619303-87-6P
	619303-89-8P	619303-90-1P	619303-91-2P	619303-92-3P	619303-93-4P
	619303-94-5P	619303-95-6P	619303-96-7P	619303-97-8P	619303-98-9P
	619303-99-0P	619304-00-6P	619304-01-7P	619304-02-8P	619304-03-9P
	619304-04-0P	619304-05-1P	619304-06-2P	619304-07-3P	619304-08-4P
	619304-09-5P	619304-10-8P	619304-11-9P	619304-12-0P	619304-13-1P
	619304-14-2P	619304-15-3P	619304-16-4P	619304-17-5P	619304-18-6P
	619304-19-7P	619304-20-0P	619304-21-1P	619304-22-2P	619304-23-3P
	619304-24-4P	619304-25-5P	619304-26-6P	619304-27-7P	619304-28-8P
	619304-29-9P	619304-30-2P	619304-31-3P	619304-32-4P	
	619304-33-5P	619304-34-6P	619304-35-7P	619304-36-8P	
	619304-37-9P	619304-38-0P	619304-39-1P	619304-40-4P	619304-41-5P
	619304-42-6P	619304-43-7P	619304-44-8P	619304-45-9P	619304-46-0P
	619304-47-1P	619304-48-2P	619304-49-3P	619304-50-6P	619304-51-7P
	619304-52-8P	619304-53-9P	619304-54-0P	619304-55-1P	619304-56-2P
	619304-57-3P	619304-58-4P	619304-59-5P	619304-60-8P	619304-61-9P

619304-62-0P	619304-63-1P	619304-64-2P	619304-65-3P	619304-66-4P
619304-67-5P	619304-69-7P	619304-70-0P	619304-71-1P	619304-72-2P
619304-73-3P	619304-74-4P	619304-75-5P	619304-76-6P	619304-77-7P
619304-78-8P	619304-79-9P	619304-80-2P	619304-81-3P	619304-82-4P
619304-83-5P	619304-84-6P	619304-85-7P	619304-86-8P	619304-87-9P
619304-88-0P	619304-89-1P	619304-90-4P	619304-91-5P	619304-92-6P
619304-93-7P	619304-94-8P	619304-95-9P	619304-96-0P	619304-97-1P
619304-98-2P	619305-02-1P	619305-05-4P	619305-06-5P	619305-07-6P
619305-08-7P	619305-09-8P	619305-10-1P	619305-11-2P	619305-12-3P
619305-13-4P	619305-14-5P	619305-15-6P	619305-16-7P	619305-17-8P
619305-18-9P	619305-19-0P	619305-20-3P	619305-21-4P	619305-22-5P
619305-24-7P	619305-25-8P	619305-26-9P	619305-29-2P	619305-31-6P
619305-32-7P	619305-33-8P	619305-34-9P	619305-35-0P	619305-36-1P
619305-37-2P	619308-25-7P	619308-26-8P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT 87-13-8 4806-81-9, 2-Cyclohexylaniline 61098-37-1 63503-60-6,
3-Chlorophenylboronic acid 95750-97-3 174855-53-9 204078-48-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

IT 65774-93-8P 619306-82-0P 619306-83-1P 619306-84-2P 619306-85-3P
619306-86-4P 619306-87-5P 619306-88-6P 619306-89-7P 619306-90-0P
619306-91-1P 619306-93-3P 619306-94-4P 619306-95-5P 619306-96-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

RE.CNT 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) American Cyanamid Co; EP 1021413 A1 1999 HCPLUS
- (2) American Cyanamid Co; NO 2000001755 A 1999 HCPLUS
- (3) American Cyanamid Co; CA 2303449 A 1999 HCPLUS
- (4) American Cyanamid Co; BR 9812727 A 1999 HCPLUS
- (5) American Cyanamid Co; AU 9869685 A 1999 HCPLUS
- (6) American Cyanamid Co; WO 9918076 A1 1999 HCPLUS
- (7) American Cyanamid Co; US 200125047 A 2001
- (8) American Cyanamid Co; US 200146989 A 2001
- (9) American Cyanamid Co; US 6228869 B1 2001 HCPLUS
- (10) American Cyanamid Co; US 6498167 B2 2001 HCPLUS
- (11) American Cyanamid Co; US 6548524 B2 2001 HCPLUS
- (12) Anon; 1960
- (13) Aventis Pharmaceuticals Products Inc; WO 0190101 A1 2001 HCPLUS
- (14) Aventis Pharmaceuticals Products Inc; EP 1296972 A1 2001 HCPLUS
- (15) Aventis Pharmaceuticals Products Inc; BR 2001011206 A 2001 HCPLUS
- (16) Aventis Pharmaceuticals Products Inc; NO 2002005601 A 2001 HCPLUS
- (17) Bartroli, J; Journal of Medicinal Chemistry 1998, V41(11), P1855 HCPLUS
- (18) Beecham Group Ltd; CA 1093551 A 1980 HCPLUS
- (19) Beecham Group Ltd; PL 110458 B1 1980 HCPLUS
- (20) Beecham Group Ltd; PL 110478 B1 1980 HCPLUS
- (21) Beecham Group Ltd; GB 1568962 A 1980 HCPLUS
- (22) Beecham Group Ltd; GB 1579362 A 1980 HCPLUS
- (23) Beecham Group Ltd; FR 2329279 A1 1980
- (24) Beecham Group Ltd; FR 2383950 A1 1980 HCPLUS
- (25) Beecham Group Ltd; DE 2811483 A1 1980 HCPLUS
- (26) Beecham Group Ltd; AT 350725 B 1980 HCPLUS
- (27) Beecham Group Ltd; AT 356813 B 1980 HCPLUS
- (28) Beecham Group Ltd; US 4166817 A 1980 HCPLUS
- (29) Beecham Group Ltd; ES 462782 A1 1980 HCPLUS
- (30) Beecham Group Ltd; IL 50797 A 1980 HCPLUS
- (31) Beecham Group Ltd; AU 508264 B 1980 HCPLUS
- (32) Beecham Group Ltd; JP 52-077081 A 1980 HCPLUS
- (33) Beecham Group Ltd; JP 53-121789 A 1980 HCPLUS

(34) Beecham Group Ltd; CH 629209 A 1980 HCAPLUS
 (35) Beecham Group Ltd; AU 7419164 A 1980
 (36) Beecham Group Ltd; FI 7603112 A 1980 HCAPLUS
 (37) Beecham Group Ltd; NO 7603695 A 1980 HCAPLUS
 (38) Beecham Group Ltd; DK 7604927 A 1980 HCAPLUS
 (39) Beecham Group Ltd; AT 7608009 A 1980 HCAPLUS
 (40) Beecham Group Ltd; NL 7612073 A 1980 HCAPLUS
 (41) Beecham Group Ltd; SE 7612082 A 1980 HCAPLUS
 (42) Beecham Group Ltd; AT 7802859 A 1980 HCAPLUS
 (43) Beecham Group Ltd; BE 847698 A1 1980 HCAPLUS
 (44) Checchi, S; Gazzetta Chimica Italiana 1956, V86, P631 HCAPLUS
 (45) Checchi, S; Gazzetta Chimica Italiana 1957, V87, P597 HCAPLUS
 (46) Elworthy, T; Journal of Medicinal Chemistry 1997, V40(17), P2674 HCAPLUS
 (47) F Hoffmann-La Roche A-G; JP 2001514163 A 1999
 (48) F Hoffmann-La Roche A-G; US 645550 B1 1999
 (49) F Hoffmann-La Roche A-G; BR 9811988 A 1999 HCAPLUS
 (50) F Hoffmann-La Roche A-G; WO 9910313 A1 1999 HCAPLUS
 (51) F Hoffmann-La Roche A-G; EP 1005445 A1 2001 HCAPLUS
 (52) F Hoffmann-La Roche A-G; NO 2000000841 A 2001 HCAPLUS
 (53) F Hoffmann-La Roche A-G; JP 2001514162 A 2001
 (54) F Hoffmann-La Roche A-G; CA 2301377 A 2001 HCAPLUS
 (55) F Hoffmann-La Roche A-G; NZ 502813 A 2001 HCAPLUS
 (56) F Hoffmann-La Roche A-G; US 6229011 B1 2001 HCAPLUS
 (57) F Hoffmann-La Roche A-G; AU 739511 B 2001 HCAPLUS
 (58) F Hoffmann-La Roche A-G; BR 9811730 A 2001 HCAPLUS
 (59) F Hoffmann-La Roche A-G; AU 9892620 A 2001 HCAPLUS
 (60) F Hoffmann-La Roche A-G; WO 9910312 A1 2001 HCAPLUS
 (61) J Uriach & Cia S A; JP 10-507205 A 1999
 (62) J Uriach & Cia S A; ES 2107376 A1 1999 HCAPLUS
 (63) J Uriach & Cia S A; ES 2107376 B1 1999 HCAPLUS
 (64) J Uriach & Cia S A; ES 2112774 A1 1999 HCAPLUS
 (65) J Uriach & Cia S A; ES 2112774 B1 1999 HCAPLUS
 (66) J Uriach & Cia S A; CA 2201478 A 1999 HCAPLUS
 (67) J Uriach & Cia S A; US 5888941 A 1999 HCAPLUS
 (68) J Uriach & Cia S A; EP 783502 A1 1999 HCAPLUS
 (69) J Uriach & Cia S A; BR 9606546 A 1999 HCAPLUS
 (70) J Uriach & Cia S A; AU 9667889 A 1999 HCAPLUS
 (71) J Uriach & Cia S A; NO 9701471 A 1999 HCAPLUS
 (72) J Uriach & Cia S A; WO 9705131 A1 1999 HCAPLUS
 (73) Lederle Japan Ltd; JP 07-267960 A 1995 HCAPLUS
 (74) Levin, J; US 2002132826 A 2002
 (75) Merck Patent GmbH; WO 0228820 A1 2002 HCAPLUS
 (76) Merck Patent GmbH; AU 2001089891 A 2002 HCAPLUS
 (77) Merck Patent GmbH; FR 2815030 A1 2002 HCAPLUS
 (78) Mustazza, C; Journal of Heterocyclic Chemistry 2001, V38(5), P1119 HCAPLUS
 (79) Nissan Chemical Industries Ltd; JP 2001302666 A 2001 HCAPLUS
 (80) Novinson, T; Journal of Medicinal Chemistry 1977, V20(2), P296 HCAPLUS
 (81) Pfizer Products Inc; WO 02024613 A2 2002
 (82) Pfizer Products Inc; WO 02024613 A3 2002
 (83) Pfizer Products Inc; US 2002137961 A 2002 HCAPLUS
 (84) Pfizer Products Inc; US 6541473 B2 2002 HCAPLUS
 (85) Pola Chemical Industries Inc; JP 02-275882 A 1991 HCAPLUS
 (86) Pola Chemical Industries Inc; CN 1041943 A 1991
 (87) Pola Chemical Industries Inc; CA 1330079 A 1991 HCAPLUS
 (88) Pola Chemical Industries Inc; ES 2088882 T3 1991 HCAPLUS
 (89) Pola Chemical Industries Inc; EP 369145 A2 1991 HCAPLUS
 (90) Pola Chemical Industries Inc; US 4992442 A 1991 HCAPLUS
 (91) Smithkline Beecham Corp; EP 1067894 A2 1999 HCAPLUS
 (92) Smithkline Beecham Corp; JP 2002515411 A 1999
 (93) Smithkline Beecham Corp; CA 2332531 A 1999 HCAPLUS
 (94) Smithkline Beecham Corp; US 6518267 B1 1999 HCAPLUS
 (95) Smithkline Beecham Corp; WO 9959526 A2 1999 HCAPLUS
 (96) Smithkline Beecham Corp; WO 9959526 A3 1999 HCAPLUS
 (97) Takamizawa, A; Chemical & Pharmaceutical Bulletin 1968, V16(11), P2195
 HCAPLUS
 (98) Yoshitomi Pharmaceutical Industries Ltd; US 4918074 A 1990 HCAPLUS


(99) Yoshitomi Pharmaceutical Industries Ltd; JP 60-193990 A 1990 HCAPLUS
 (100) Yoshitomi Pharmaceutical Industries Ltd; JP 60-246387 A 1990 HCAPLUS
 (101) Yoshitomi Pharmaceutical Industries Ltd; JP 62-077387 A 1990 HCAPLUS
 (102) Yoshitomi Pharmaceutical Industries Ltd; JP 62-270584 A 1990 HCAPLUS
 (103) Yoshitomi Pharmaceutical Industries Ltd; JP 05-194401 A 1995 HCAPLUS
 (104) Yoshitomi Pharmaceutical Industries Ltd; JP 06-041080 A 1995 HCAPLUS
 (105) Yoshitomi Pharmaceutical Industries Ltd; CA 2117096 C 1995 HCAPLUS
 (106) Yoshitomi Pharmaceutical Industries Ltd; ES 2148179 T3 1995 HCAPLUS
 (107) Yoshitomi Pharmaceutical Industries Ltd; US 5478838 A 1995 HCAPLUS
 (108) Yoshitomi Pharmaceutical Industries Ltd; EP 641781 A1 1995 HCAPLUS
 (109) Yoshitomi Pharmaceutical Industries Ltd; WO 9305021 A1 1995 HCAPLUS

IT 619306-29-5 619306-35-3 619306-36-4

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)


RN 619306-29-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(diethylamino)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619306-35-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(2-aminoethyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)-7-(diethylamino)- (9CI) (CA INDEX NAME)



RN 619306-36-4 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(dimethylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 619304-33-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

RN 619304-33-5 HCPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(diethylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



L24 ANSWER 6 OF 6 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:542450 HCPLUS
 DN 127:220669
 ED Entered STN: 25 Aug 1997
 TI Pyrazolopyrimidines as CRF receptor antagonists
 IN Chen, Chen; Webb, Thomas R.; McCarthy, James R.; Moran, Terence J.; Wilcoxon, Keith M.
 PA Janssen Pharmaceutica N.V., Belg.; Neurocrine Biosciences, Inc.
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D487-04
 ICS A61K031-495
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729109	A1	19970814	WO 1997-EP459	19970130
	W:	AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

CA 2233285	AA	19970814	CA 1997-2233285	19970130
AU 9715991	A1	19970828	AU 1997-15991	19970130
AU 713673	B2	19991209		
EP 880523	A1	19981202	EP 1997-902295	19970130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1205009	A	19990113	CN 1997-191382	19970130
CN 1090189	B	20020904		
BR 9707391	A	19990720	BR 1997-7391	19970130
NZ 330119	A	20000228	NZ 1997-330119	19970130
JP 2000503661	T2	20000328	JP 1997-528123	19970130
JP 3356291	B2	20021216		
JP 2002121194	A2	20020423	JP 2001-265611	19970130
EE 4282	B1	20040415	EE 1998-124	19970130
TW 449599	B	20010811	TW 1997-86101373	19970205
ZA 9700989	A	19980806	ZA 1997-989	19970206
NO 9801357	A	19980803	NO 1998-1357	19980325
NO 310292	B1	20010618		
US 2003125341	A1	20030703	US 1999-117717	19990302
US 6664261	B2	20031216		
US 2004127483	A1	20040701	US 2003-665740	20030919
PRAI US 1996-11279P	P	19960207		
US 1996-27688P	P	19961008		
JP 1997-528123	A3	19970130		
WO 1997-EP459	W	19970130		
US 1999-117717	A1	19990302		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9729109	ICM	C07D487-04
	ICS	A61K031-495
WO 9729109	ECLA	C07D487/04+239C+231C
US 2003125341	NCL	514/262.100
	ECLA	C07D487/04+239C+231C
US 2004127483	NCL	514/217.060
	ECLA	C07D487/04+239C+231C

OS MARPAT 127:220669
GI



AB Title compds. I [R = (un)substituted Ph, pyridyl; R1 = substituted NH₂, (un)substituted alkoxy; R2 = alkyl, alkoxy, alkylthio; R3 = H, alkyl, alkylsulfonyl, alkylsulfoxy, alkylthio] having CRF receptor antagonistic properties, were prepared. Thus, I [R = 2,4-Cl₂C₆H₃, R1 = N-propyl-N-cyclopropylmethylamino, R2 = Me, R3 = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH₂CO₂Et, chlorinating I [R = 2,4-Cl₂C₆H₃, R1 = OH, R2 = Me, R3 = H] and aminating I [R1 = Cl]. II had a Ki for CRF receptor inhibition of <250 nM.

ST aminopyrazolopyrimidine prep CRF receptor antagonist

IT Corticotropin releasing factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antagonists; preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

IT 16142-51-1P 104906-17-4P 195054-42-3P 195054-43-4P 195054-44-5P

195054-45-6P	195054-46-7P	195054-47-8P	195054-48-9P	195054-49-0P
195054-50-3P	195054-51-4P	195054-52-5P	195054-53-6P	195054-54-7P
195054-55-8P	195054-56-9P	195054-57-0P	195054-58-1P	195054-59-2P
195054-60-5P	195054-61-6P	195054-62-7P	195054-63-8P	195054-64-9P
195054-65-0P	195054-66-1P	195054-67-2P	195054-68-3P	195054-69-4P
195054-70-7P	195054-71-8P	195054-72-9P	195054-73-0P	195054-74-1P
195054-75-2P	195054-76-3P	195054-77-4P	195054-78-5P	195054-79-6P
195054-80-9P	195054-81-0P	195054-82-1P	195054-83-2P	195054-84-3P
195054-86-5P	195054-88-7P	195054-90-1P	195054-92-3P	195054-94-5P
195054-96-7P	195054-97-8P	195054-99-0P	195055-01-7P	195055-03-9P
195055-05-1P	195055-07-3P	195055-09-5P	195055-11-9P	195055-13-1P
195055-15-3P	195055-18-6P	195055-21-1P	195055-24-4P	195055-27-7P
195055-29-9P	195055-31-3P	195055-33-5P	195055-34-6P	195055-35-7P
195055-36-8P	195055-37-9P	195055-38-0P	195055-39-1P	195055-40-4P
195055-41-5P	195055-42-6P	195055-43-7P	195055-44-8P	195055-45-9P
195055-46-0P	195055-47-1P	195055-48-2P	195055-49-3P	195055-50-6P
195055-51-7P	195055-52-8P	195055-53-9P	195055-54-0P	195055-55-1P
195055-56-2P	195055-57-3P	195055-58-4P	195055-59-5P	195055-60-8P
195055-61-9P	195055-66-4P	195055-68-6P	195055-69-7P	195055-70-0P
195055-71-1P	195055-72-2P	195055-73-3P	195055-74-4P	
195055-75-5P	195055-76-6P	195055-77-7P	195055-78-8P	195055-79-9P
195055-80-2P	195055-81-3P	195055-82-4P	195055-83-5P	195055-84-6P
195055-85-7P	195055-86-8P	195055-87-9P	195055-88-0P	195055-89-1P
195055-90-4P	195055-91-5P	195055-92-6P	195055-93-7P	195055-94-8P
195055-95-9P	195055-96-0P	195055-97-1P	195055-98-2P	195055-99-3P
195056-00-9P	195056-01-0P	195059-24-6P	195059-25-7P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

IT 141-97-9, Ethyl acetoacetate 7533-40-6, (S)-Leucinol 26389-60-6

53448-09-2 195055-62-0 195055-65-3 195055-67-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

IT 195055-63-1P 195055-64-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)


IT 195055-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

RN 195055-71-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



=> b uspatall

FILE 'USPATFULL' ENTERED AT 15:48:24 ON 25 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:48:24 ON 25 OCT 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn l30 tot


L30 ANSWER 1 OF 2 USPATFULL on STN
 AN 2005:50527 USPATFULL
 TI Pharmaceutical composition for the prevention and treatment of addiction
 in a mammal
 IN Coe, Jotham Wadsworth, Niantic, CT, UNITED STATES
 Iredale, Philip A., Clinton, CT, UNITED STATES
 McHardy, Stanton Furst, Coventry, RI, UNITED STATES
 McLean, Stafford, Stonington, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005043327 A1 20050224
 AI US 2004-870209 A1 20040617 (10)
 PRAI US 2003-496803P 20030821 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
 10017-5612
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2088

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 737828-12-5
 (opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)
 RN 737828-12-5 USPATFULL
 CN Pyrazolo[1,5-a]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-methyl-7-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



IT 737828-12-5 737828-13-6
 (opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

L30 ANSWER 2 OF 2 USPATFULL on STN


AN 2004:203946 USPATFULL
 TI Cannabinoid receptor ligands and uses thereof
 IN Griffith, David A., Old Saybrook, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2004157838 A1 20040812
 AI US 2004-762959 A1 20040121 (10)
 PRAI US 2003-446450P 20030210 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON,
 CT, 06340
 CLMN Number of Claims: 127
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of Formula (I) that act as cannabinoid receptor ligands and
 their uses in the treatment of diseases linked to the mediation of the
 cannabinoid receptors in animals are described herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 737828-11-4P, 7-(1-tert-Butylazetidin-3-yloxy)-3-(4-chlorophenyl)-
 2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor
 ligands (antagonists) for treating diseases mediated by cannabinoid
 receptors)
 RN 737828-11-4 USPATFULL
 CN Pyrazolo[1,5-a]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[(1-
 (1,1-dimethylethyl)-3-azetidinyl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



IT 737828-11-4P, 7-(1-tert-Butylazetidin-3-yloxy)-3-(4-chlorophenyl)-
 2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine 737828-12-5P
 737828-13-6P
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor
 ligands (antagonists) for treating diseases mediated by cannabinoid
 receptors)

=> d bib abs hitstr l31 tot

L31 ANSWER 1 OF 4 USPATFULL on STN
 AN 2005:69509 USPATFULL
 TI Fused-aryl and heteroaryl derivatives as modulators of metabolism and
 the prophylaxis and treatment of disorders related thereto
 IN Jones, Robert M., San Diego, CA, UNITED STATES
 Semple, Graeme, San Diego, CA, UNITED STATES
 Xiong, Yifeng, San Diego, CA, UNITED STATES
 Shin, Young-Jun, San Diego, CA, UNITED STATES
 Ren, Albert S., San Diego, CA, UNITED STATES
 Calderon, Imelda, San Diego, CA, UNITED STATES
 Fioravanti, Beatriz, Tucson, AZ, UNITED STATES

Choi, Jin Sun Karoline, San Diego, CA, UNITED STATES
 Sage, Carleton R., Cardiff-by-the-Sea, CA, UNITED STATES

PI US 2005059650 A1 20050317
 AI US 2004-890549 A1 20040713 (10)
 PRAI US 2003-487443P 20030714 (60)
 US 2003-510644P 20031010 (60)

DT Utility

FS APPLICATION

LREP COZEN O'CONNOR, P.C., 1900 MARKET STREET, PHILADELPHIA, PA, 19103-3508

CLMN Number of Claims: 100

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 12764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. ##STR1##

Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 832718-95-3P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine
 832718-96-4P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832718-97-5P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832718-98-6P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832718-99-7P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-00-3P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidine 832719-01-4P, 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine 832719-02-5P, 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-03-6P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-04-7P, 4-[[3-(2-Fluoro-4-propionylsulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-05-8P, 4-[[3-(4-Cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-06-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-07-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-08-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-09-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-10-5P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-11-6P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidine 832719-12-7P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-13-8P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-14-9P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-15-0P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]

a]pyrimidine 832719-16-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidine 832719-17-2P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine 832719-18-3P, 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-19-4P, 4-[[3-(2-Fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-20-7P, 4-[[3-(2-Fluoro-4-propionylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-21-8P, 4-[[3-(4-Cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-22-9P, 4-[[3-(2-Fluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-23-0P, 4-[[3-(2,5-Difluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-24-1P, 4-[[3-(4-Fluoro-6-methoxypyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-25-2P, 4-[[3-(6-Methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-26-3P, 4-[[3-(2,5-Difluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]piperidine-1-carboxylic acid isopropyl ester 832719-27-4P, 2,5-Difluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-28-5P, 7-[[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-29-6P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-30-9P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-31-0P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-32-1P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-33-2P, 3-Fluoro-4-[7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-34-3P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]oxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-35-4P, 3-(2-Fluoro-4-methylsulfonylphenyl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-36-5P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]-N-propionylbenzenesulfonamide 832719-37-6P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-38-7P, 3-Fluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide 832719-39-8P, 3-(2,5-Difluoro-4-methylsulfonylphenyl)-7-[[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile 832719-40-1P, 3-(4-Fluoro-6-methoxypyridin-3-yl)-7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidine 832719-41-2P, 7-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine 832719-42-3P, 2,5-Difluoro-4-[7-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)cyclohexyloxy]-2-methylpyrazolo[1,5-a]pyrimidin-3-yl]benzenesulfonamide
 (drug candidate; preparation of fused aryl and heteroaryl derivs., in particular pyrazolopyrimidines, as modulators of G-coupled protein receptor and their use in the treatment of diabetes, hyperglycemia and related diseases)


RN 832718-95-3 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832718-96-4 USPATFULL

CN Propanamide, N-[[3-fluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832718-97-5 USPATFULL

CN Benzonitrile, 3-fluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832718-98-6 USPATFULL

CN Benzenesulfonamide, 3-fluoro-4-[7-[[4-[[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832718-99-7 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-7-[[4-[[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-00-3 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3- (4-fluoro-6-methoxy-3-pyridinyl)-7- [[4- [3- (1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-01-4 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3- (6-methoxy-2-methyl-3-pyridinyl)-7- [[4- [3- (1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-02-5 USPATFULL

CN Benzenesulfonamide, 2,5-difluoro-4-[7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-03-6 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-(methylsulfonyl)phenyl]phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-04-7 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-[(1-oxopropyl)amino]sulfonyl]phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-05-8 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-06-9 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[4-(aminosulfonyl)-2-fluorophenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester
(9CI) (CA INDEX NAME)




RN 832719-07-0 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2,5-difluoro-4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-08-1 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-fluoro-6-methoxy-3-pyridinyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-09-2 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(6-methoxy-2-methyl-3-pyridinyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-10-5 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[4-(aminosulfonyl)-2,5-difluorophenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester
(9CI) (CA INDEX NAME)


RN 832719-11-6 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-12-7 USPATFULL

CN Propanamide, N-[(3-fluoro-4-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 832719-13-8 USPATFULL

CN Benzonitrile, 3-fluoro-4-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]-(9CI) (CA INDEX NAME)




RN 832719-14-9 USPATFULL

CN Benzenesulfonamide, 3-fluoro-4-[7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl] - (9CI) (CA INDEX NAME)




RN 832719-15-0 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy] - (9CI) (CA INDEX NAME)




RN 832719-16-1 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3- (4-fluoro-6-methoxy-3-pyridinyl)-7- [[1- [3- (1- methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-17-2 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3- (6-methoxy-2-methyl-3-pyridinyl)-7- [[1- [3- (1- methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-18-3 USPATFULL

CN Benzenesulfonamide, 2,5-difluoro-4-[7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)


RN 832719-19-4 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-20-7 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-fluoro-4-[(1-oxopropyl)amino]sulfonyl]phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-21-8 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 832719-22-9 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[4-(aminosulfonyl)-2-fluorophenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-23-0 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-24-1 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(4-fluoro-6-methoxy-3-pyridinyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)


RN 832719-25-2 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-(6-methoxy-2-methyl-3-pyridinyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-26-3 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[3-[4-(aminosulfonyl)-2,5-difluorophenyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 832719-27-4 USPATFULL

CN Benzenesulfonamide, 2,5-difluoro-4-[[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]-
(9CI) (CA INDEX NAME)




RN 832719-28-5 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-7-
[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI)
(CA INDEX NAME)




RN 832719-29-6 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[(4-fluoro-6-methoxy-3-pyridinyl)-2-methyl-7-
[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI)
(CA INDEX NAME)




RN 832719-30-9 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]-(9CI) (CA INDEX NAME)




RN 832719-31-0 USPATFULL

CN Benzenesulfonamide, 3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]-(9CI) (CA INDEX NAME)




RN 832719-32-1 USPATFULL

CN Benzonitrile, 3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)




RN 832719-33-2 USPATFULL

CN Propanamide, N-[[3-fluoro-4-[2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832719-34-3 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]oxy]- (9CI)
 (CA INDEX NAME)




RN 832719-35-4 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI)
 (CA INDEX NAME)




RN 832719-36-5 USPATFULL

CN Propanamide, N-[3-fluoro-4-[2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 832719-37-6 USPATFULL

CN Benzonitrile, 3-fluoro-4-[2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-38-7 USPATFULL

CN Benzenesulfonamide, 3-fluoro-4-[2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 832719-39-8 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-[2,5-difluoro-4-(methylsulfonyl)phenyl]-2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]- (9CI) (CA INDEX NAME)




RN 832719-40-1 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-fluoro-6-methoxy-3-pyridinyl)-2-methyl-7-[(4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]- (9CI) (CA INDEX NAME)




RN 832719-41-2 USPATFULL

CN Pyrazolo[1,5-a]pyrimidine, 3-(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-7-[(4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl)oxy]- (9CI) (CA INDEX NAME)



RN 832719-42-3 USPATFULL
 CN Benzenesulfonamide, 2,5-difluoro-4-[2-methyl-7-[[4-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]cyclohexyl]oxy]pyrazolo[1,5-a]pyrimidin-3-yl]-
 (9CI) (CA INDEX NAME)



L31 ANSWER 2 OF 4 USPATFULL on STN
 AN 2004:165993 USPATFULL
 TI Pyrazolopyrimidines as CRF receptor antagonists
 IN Chen, Chen, San Diego, CA, UNITED STATES
 Webb, Thomas R., Olivenhain, CA, UNITED STATES
 McCarthy, James R., Zionsville, IN, UNITED STATES
 Moran, Terence J., San Diego, CA, UNITED STATES
 Wilcoxen, Keith M., San Diego, CA, UNITED STATES
 Huang, Charles Q., San Diego, CA, UNITED STATES
 PA Neurocrine Biosciences, Inc., San Diego, CA, UNITED STATES, 92121-1102
 (U.S. corporation)
 PI US 2004127483 A1 20040701
 AI US 2003-665740 A1 20030919 (10)

RLI Continuation of Ser. No. US 1999-117717, filed on 2 Mar 1999, GRANTED,
 Pat. No. US 6664261 A 371 of International Ser. No. WO 1997-EP459, filed
 on 30 Jan 1997, UNKNOWN
 PRAI US 1996-11279P 19960207 (60)
 US 1996-27688P 19961008 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1459


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns compounds of formula ##STR1##

including the stereoisomers and the pharmaceutically acceptable acid
 addition salt forms thereof, wherein R.sup.1 is NR.sup.4R.sup.5 or
 OR.sup.5; R.sup.2 is C.sub.1-6alkyl, C.sub.1-6alkyloxy or
 C.sub.1-6alkylthio; R.sup.3 is hydrogen, C.sub.1-6alkyl,
 C.sub.1-6alkylsulfonyl, C.sub.1-6alkylsulfoxy or C.sub.1-6alkylthio;
 R.sup.4 is hydrogen, C.sub.1-6alkyl, mono- or di(C.sub.3-
 6cycloalkyl)methyl, C.sub.3-6cycloalkyl, C.sub.3-6alkenyl,
 hydroxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyloxyC.sub.1-6alkyl or
 C.sub.1-6alkyloxyC.sub.1-6alkyl; R.sup.5 is C.sub.1-8alkyl, mono- or
 di(C.sub.3-6cycloalkyl)methyl, A.sup.1CH.sup.2, C.sub.1-6alkyloxyC.sub.1-
 6alkyl, hydroxyC.sub.1-6alkyl, C.sub.3-6alkenyl, thi enylmethyl,
 furanylmethyl, C.sub.1-6alkylthioC.sub.1-6alkyl, morpholinyl, mono- or
 di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, di(C.sub.1-6alkyl)amino,
 C.sub.1-6alkylcarbonylC.sub.1-6alkyl, C.sub.1-6alkyl substituted with
 imidazolyl; or a radical of formula --Alk--O--CO--Ar.sup.1; or R.sup.4
 and R.sup.5 taken together with the nitrogen atom to which they are
 attached may form an optionally substituted pyrrolidinyl, piperidinyl,
 homopiperidinyl or morpholinyl group; having CRF receptor antagonistic
 properties; pharmaceutical compositions containing such compounds as
 active ingredients; methods of treating disorders related to
 hypersecretion of CRF such as depression, anxiety, substance abuse, by
 administering an effective amount of a compound of formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 195055-71-1P
 (preparation of aminopyrazolopyrimidines as CRF receptor antagonists)
 RN 195055-71-1 USPATFULL
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-
 piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



L31 ANSWER 3 OF 4 USPATFULL on STN
 AN 2003:181508 USPATFULL
 TI PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS
 IN CHEN, CHEN, SAN DIEGO, CA, UNITED STATES
 WEBB, THOMAS R., OLIVENHAIN, CA, UNITED STATES

MACARTY, JAMES R., SOLANA BEACH, CA, UNITED STATES
 MORAN, TERENCE J., SAN DIEGO, CA, UNITED STATES
 WILCOXEN, KEITH M., GROTON LONG POINT, CA, UNITED STATES
 HUANG, CHARLES, SAN DIEGO, CA, UNITED STATES

PI US 2003125341 A1 20030703
 US 6664261 B2 20031216
 AI US 1999-117717 A1 19990302 (9)
 WO 1997-EP459 19970130

DT Utility
 FS APPLICATION

LREP SCULLY, SCOTT, MURPHY & PRESSER, 400Garden City Plaza, Garden City, NY,
 11530-0299

CLMN Number of Claims: 13
 ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1438

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns compounds of formula ##STR1##

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R.^{sup.1} is NR.^{sup.4}R.^{sup.5} or OR.^{sup.5}; R.^{sup.2} is C._{sub.1-6}alkyl, C._{sub.1-6}alkyloxy or C._{sub.1-6}alkylthio; R.^{sup.3} is hydrogen, C._{sub.1-6}alkyl, C._{sub.1-6}alkylsulfonyl, C._{sub.1-6}alkylsulfoxy or C._{sub.1-6}alkylthio; R.^{sup.4} is hydrogen, C._{sub.1-6}alkyl, mono- or di(C._{sub.3-6}cycloalkyl)methyl, C._{sub.3-6}cycloalkyl, C._{sub.3-6}alkenyl, hydroxyC._{sub.1-6}alkyl, C._{sub.1-6}alkylcarbonyloxyC._{sub.1-6}alkyl or C._{sub.1-6}alkyloxyC._{sub.1-6}alkyl; R.^{sup.5} is C._{sub.1-8}alkyl, mono- or di(C._{sub.3-6}cycloalkyl)methyl, Ar.^{sup.1}CH._{sub.2}, C._{sub.1-6}alkyloxyC._{sub.1-6}alkyl, hydroxyC._{sub.1-6}alkyl, C._{sub.3-6}alkenyl, thienylmethyl, furanylmethyl, C._{sub.1-6}alkylthioC._{sub.1-6}alkyl, morpholinyl, mono- or di(C._{sub.1-6}alkyl)aminoC._{sub.1-6}alkyl, di(C._{sub.1-6}alkyl)amino, C._{sub.1-6}alkylcarbonylC._{sub.1-6}alkyl, C._{sub.1-6}alkyl substituted with imidazolyl; or a radical of formula --Alk-O--CO--Ar.^{sup.1}; or R.^{sup.4} and R.^{sup.5} taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 195055-71-1P

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

RN 195055-71-1 USPATFULL

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



L31 ANSWER 4 OF 4 USPAT2 on STN

AN 2003:181508 USPAT2
 TI Pyrazolopyrimidines as CRF receptor antagonists
 IN Chen, Chen, San Diego, CA, United States
 Webb, Thomas R., Olivenhain, CA, United States
 McCarthy, James R., Solana Beach, CA, United States
 Moran, Terence J., San Diego, CA, United States
 Wilcoxon, Keith M., Groton Long Point, CA, United States
 Huang, Charles, San Diego, CA, United States
 PA Neurocrine Biosciences, Inc., San Diego, CA, United States (U.S.
 corporation)

PI US 6664261 B2 20031216
 WO 9729109 19970814

AI US 1999-117717 19990302 (9)
 WO 1997-EP459 19970130
 19990302 PCT 371 date

PRAI US 1996-11279P 19960207 (60)
 US 1996-27688P 19961008 (60)

DT Utility
 FS GRANTED

EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Truong,
 Tamthom N.

LREP Seed IP Law Group PLLC

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 1346

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns compounds of formula ##STR1##

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R.sup.1 is NR.sup.4R.sup.5 or OR.sup.5; R.sup.2 is C.sub.1-6alkyl, C.sub.1-6alkyloxy or C.sub.1-6alkylthio; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylsulfonyl, C.sub.1-6alkylsulfoxy or C.sub.1-6alkylthio; R.sup.4 is hydrogen, C.sub.1-6alkyl, mono- or di(C.sub.3-6cycloalkyl)methyl, C.sub.3-6cycloalkyl, C.sub.3-6alkenyl, hydroxyc.sub.1-6alkyl, C.sub.1-6alkylcarbonyloxyC.sub.1-6alkyl or C.sub.1-6alkyloxyC.sub.1-6alkyl; R.sup.5 is C.sub.1-6alkyl, mono- or di(C.sub.3-6cycloalkyl)methyl, Ar.sup.1CH.sub.2, C.sub.1-6alkyloxyC.sub.1-6alkyl, hydroxyc.sub.1-6alkyl, C.sub.3-6alkenyl, thiethylmethyl, furanylmethyl, C.sub.1-6alkylthioC.sub.1-6alkyl, morpholinyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, C.sub.1-6alkyl substituted with imidazolyl; or a radical of formula --Alk--O--CO--Ar.sup.1; or R.sup.4 and R.sup.5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 195055-71-1P

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

RN 195055-71-1 USPAT2

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



=> b home
FILE 'HOME' ENTERED AT 15:49:11 ON 25 OCT 2005

=>